Bausch Health Companies Inc. (BHC) 2015 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning. My name is Heidi and I will be your conference operator today. At this time, I would like to welcome everyone to the Valeant fourth quarter 2015 unaudited financial results conference call.

    早安。我叫Heidi,今天將擔任各位的電話會議接線員。此刻,我想歡迎各位參加Valeant 2015年第四季未經審計財務結果電話會議。

  • (Operator Instructions)

    (接線員指示)

  • Thank you. Head of Investor Relations, Laurie Little, you may begin your conference.

    謝謝。投資人關係主管Laurie Little,您可以開始會議。

  • - Head of IR

    - Head of IR

  • Thanks Heidi. And good morning everyone and welcome to Valeant's investor conference call. Participating on today's call are Mike Pearson, Chief Executive Officer; Rob Rosiello, Chief Financial Officer; Dr. Ari Kellen, Company Group Chairman; Anne Whitaker, Company Group Chairman; and Linda LaGorga, our Treasurer. In addition to a live webcast, a copy of today's slide presentation can be found on our website, under the Investor Relations section.

    謝謝你,Heidi。各位早安,歡迎參加Valeant的投資人電話會議。今天參與會議的有:執行長Mike Pearson;財務長Rob Rosiello;公司集團主席Ari Kellen博士;公司集團主席Anne Whitaker;以及我們的財務主管(Treasurer)Linda LaGorga。除了線上即時網路直播外,今天的簡報投影片也可在我們網站的投資人關係專區取得。

  • Before we begin, our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation, as it contains important information.

    在開始之前,我們今天的簡報包含前瞻性資訊。請各位花點時間閱讀簡報開頭的前瞻性聲明說明,當中包含重要資訊。

  • In addition, this presentation contains non-GAAP financial measures. Non-GAAP financial reconciliations can be found in the press release issued earlier today and posted on our website.

    此外,本簡報包含非GAAP財務衡量指標。非GAAP財務調節表可在我們今日稍早發布並已張貼於網站的新聞稿中找到。

  • Finally, the financial guidance in this presentation is effective only as of today. It is our policy to affirm -- to update or affirm guidance only through broadly disseminated public disclosure and with that, I will turn the call over to Mike.

    最後,本簡報中的財務指引僅於今日有效。我們的政策是僅透過廣泛公開揭露來更新或確認指引;接下來我把電話交給Mike。

  • - CEO

    - CEO

  • Good morning, everyone. And thank you, Lori. Thanks for joining us. Today, we would like to cover the following topics. First, we will discuss our preliminary unaudited fourth-quarter 2015 results. Second, we are going to take you through our new tax presentation. Third, we're going to provide revised Q1 2016 financial guidance.

    各位早安。謝謝你,Lori。感謝各位加入我們。今天我們想涵蓋以下主題。第一,我們將討論2015年第四季初步未經審計的業績。第二,我們將帶各位了解我們新的稅務呈現方式。第三,我們將提供修訂後的2016年第一季財務指引。

  • Fourth, I'd like to take a few minutes to provide my perspective on the current state of the business since I've been back a couple weeks, including a revised 2016 guidance and other key business updates. Fifth, Linda LaGorga, our Treasurer, will provide a liquidity and cash flow update.

    第四,我想花幾分鐘分享我回來這幾週以來對目前業務狀況的看法,包括修訂後的2016年指引以及其他重要的業務更新。第五,我們的財務主管Linda LaGorga將提供流動性與現金流更新。

  • And finally, I'm going to address some questions that we've gotten ahead of the call. And then we will open it up to Q&A. We've added a number of slides in the Appendix around assumptions and our top 30 products which we will not be going through but are -- will be made available to you.

    最後,我將回應一些我們在會前收到的問題。接著我們會開放問答。我們在附錄新增了多張投影片,內容涉及假設以及我們前30大產品;我們不會逐一說明,但會提供給各位。

  • As we've previously disclosed, there is an ongoing review of our 2014 financials and as such, we're not able to provide year-over-year comparisons today. Financial metrics that are impacted by this include the organic growth, business unit growth, and price volume detail. What we can provide today are preliminary unaudited 2015 fourth-quarter results.

    如我們先前揭露,目前正在審查我們2014年的財務報表,因此今天無法提供年對年比較。受此影響的財務指標包括有機成長、事業單位成長,以及價格與銷量的明細。我們今天能提供的是2015年第四季初步未經審計的結果。

  • With this, let me turn the call over to our CFO, Rob Rosiello, to cover Q1 and -- Q4 and Q1.

    接下來,我把電話交給我們的財務長Rob Rosiello,請他說明第四季以及第一季的情況。

  • - CFO

    - CFO

  • On Page 5, for the quarter, our total revenue was $2.8 billion versus our guidance of $2.7 billion to $2.8 billion. GAAP EPS was a loss of $0.98. Adjusted non-GAAP EPS was $2.50, which falls below the guidance range of $2.55 to $2.65 we provided in December. The shortfall was caused by unexpected reductions in higher margin product sales, driven in part by channel destocking and negative reaction to our agreement with Walgreens.

    在第5頁,就本季而言,我們的總營收為28億美元,對比我們指引的27億至28億美元。GAAP每股盈餘為虧損0.98美元。調整後非GAAP每股盈餘為2.50美元,低於我們12月提供的2.55至2.65美元指引區間。落差主要是因高毛利產品銷售出現非預期下滑,部分原因來自通路去庫存,以及市場對我們與Walgreens協議的負面反應。

  • Cash flow from operations was $562 million. Adjusted cash flow from operations came in at $838 million, above our expected target of greater than $600 million. As a reminder, we have listed adjusted cash flow from operations on this slide but as we reported previously, we will no longer provide this metric going forward.

    營運活動現金流為5.62億美元。調整後營運活動現金流為8.38億美元,高於我們預期的超過6億美元目標。提醒各位,我們在此投影片列示了調整後營運活動現金流,但如先前所報告,我們未來將不再提供此指標。

  • On the next slide, I would like to discuss changes in Valeant's tax reporting for 2016. Historically, Valeant has reported our non-GAAP tax provision on Table 2a and 2b of the press tables that combined the tax effects of non-GAAP adjustments and the use of tax attributes and other timing issues.

    在下一張投影片,我想討論Valeant在2016年的稅務申報呈現方式變更。過去,Valeant在新聞稿表格的表2a與2b中報告我們的非GAAP所得稅費用,該數字將非GAAP調整項目的稅務影響,以及稅務屬性(tax attributes)的使用與其他時間性差異等因素合併呈現。

  • This number, approximately 5%, matched the actual cash tax that Valeant paid each year. Going forward, we will no longer include the tax effects from the use of tax attributes and other timing issues, which will, in turn, raise our reported tax rate to between 10% and 15%. This new reporting metric has no change to either cash flow or actual taxes paid.

    這個數字約為5%,與Valeant每年實際支付的現金稅額相符。未來,我們將不再納入使用稅務屬性及其他時間性差異所帶來的稅務影響,因此我們報告的稅率將提高至10%至15%。這項新的報告指標不會改變現金流或實際支付的稅額。

  • On the next page, we are also updating our previous guidance for 2015 Q1 from revenue of $2.8 billion to $3.1 billion to $2.3 billion to $2.4 billion. We expect adjusted EPS will now be $1.30 to $1.55 from $2.35 to $2.55, as compared to the guidance we provided in December.

    在下一頁,我們也將先前對2015年第一季的指引更新:營收由28億至31億美元,下修至23億至24億美元。相較於我們12月提供的指引,我們現在預期調整後每股盈餘為1.30至1.55美元,原先為2.35至2.55美元。

  • With the new tax presentation shown on the far right, adjusted EPS will be $1.18 to $1.43 for the first quarter. While most of our businesses remain strong, there are a few areas that changed since December that will impact our first quarter. First, we are realizing a decrease of roughly approximately $0.80 per share coming from the underperformance in several businesses.

    依右側所示新的稅務呈現方式,第一季調整後每股盈餘將為1.18至1.43美元。雖然我們多數業務仍然強勁,但自12月以來有幾個領域出現變化,將影響第一季表現。第一,我們正反映數個業務表現不如預期,約造成每股約0.80美元的下滑。

  • This includes slower-than-expected growth in GI, including additional product destocking. We are also realizing a slower-than-expected rebound in dermatology that includes additional product destocking and loss refills from the Philidor transition to Walgreens.

    其中包括腸胃(GI)業務成長低於預期,並包含額外的產品去庫存。我們也看到皮膚科業務反彈慢於預期,包含額外的產品去庫存,以及因Philidor轉換至Walgreens而流失的續配(refills)。

  • Finally, we are also seeing underperformance in several other US businesses, such as Ophthalmology Rx, Obagi, Solta and Women's Health as well as in Western Europe. We have also experienced headwinds from currency fluctuations, hence our guidance was first set.

    最後,我們也看到其他幾項美國業務表現不如預期,例如處方眼科(Ophthalmology Rx)、Obagi、Solta與女性健康,以及西歐地區。我們也受到匯率波動的不利影響,因此我們最初設定了該指引。

  • We also expect that another $0.20 roughly comes from the fact that even as revenue was brought down, we took little expense reduction despite this lower revenue forecast. Let me turn it back to Mike.

    我們也預期另外約0.20美元的影響,來自於即使營收下修,我們在較低的營收預測下仍幾乎沒有相應降低費用。我把電話交回給Mike。

  • - CEO

    - CEO

  • Thanks, Rob. So as you all know, I've been back from my medical leave for about two weeks. I've had a chance to review what's happening in the businesses and there's a mixed combination of some good news and some bad news. I just want to take a few minutes to sort of give you my assessment and what we plan to do about it.

    謝謝你,Rob。如各位所知,我從醫療休假回來大約兩週。我已經有機會檢視各項業務的狀況,結果是好消息與壞消息交雜。我想花幾分鐘向各位說明我的評估,以及我們打算如何因應。

  • While our businesses continue to grow we are now forecasting a lower growth rate in certain business, such as dermatology, given the continued external pressure from managed-care, the pricing environment and our slower-than-expected start in 2016.

    雖然我們的業務仍在成長,但鑑於持續受到管理式醫療(managed-care)、定價環境的外部壓力,以及我們2016年開局慢於預期,我們目前預測某些業務(例如皮膚科)的成長率將較低。

  • We continue to expect strong growth in GI, contact lenses, oral health, oncology, generics in certain emerging markets. This strong growth will be somewhat offset by some of our other businesses, including Western Europe, Ophthalmology Rx, Solta and Obagi. Many of our business units have lowered their revenue forecasts for the year from when they first put them together in the Fall.

    我們仍預期腸胃(GI)、隱形眼鏡、口腔健康、腫瘤、以及部分新興市場的學名藥將有強勁成長。這些強勁成長將在一定程度上被其他業務所抵銷,包括西歐、處方眼科(Ophthalmology Rx)、Solta與Obagi。我們許多事業單位已將全年營收預測下修,較其在秋季首次擬定時為低。

  • We have launched our Branded Access Program with Walgreens and this is a piece of the good news in mid-January with our dermatology portfolio, following the mid-February with Ophthalmology Rx and Addyi. Negotiations are underway to add networks of independent pharmacies.

    我們已與 Walgreens 推出我們的品牌可及性計畫(Branded Access Program),這是我們在 1 月中旬針對皮膚科產品組合所帶來的好消息之一,並在 2 月中旬推出眼科處方藥(Ophthalmology Rx)與 Addyi 之後延續推進。目前正進行協商,以納入獨立藥局的網絡。

  • The program itself is off to a terrific start. Within two months of launch in dermatology, approximately 30% of our dermatology scripts are flowing through Walgreens. This is approximately 2 times the volume flowing through Walgreens from when we started. More importantly, well over 90% of our doctors who were using Philidor are now using Walgreens and many new doctors are also using this channel.

    該計畫本身開局非常出色。在皮膚科領域推出後兩個月內,我們約 30% 的皮膚科處方已透過 Walgreens 流轉。這大約是我們剛開始時透過 Walgreens 流轉量的 2 倍。更重要的是,先前使用 Philidor 的醫師中,超過 90% 現在已改用 Walgreens,且也有許多新醫師開始使用此通路。

  • Walgreen's senior management, whom we met with last week, is equally excited about the program and we continue to fine-tune it to better serve our physicians and patients and improve the economics. Our brand for generic program is on track to launch sometime this summer.

    我們上週與 Walgreens 的高階管理團隊會面,他們對該計畫同樣感到振奮;我們也持續微調計畫,以更好地服務醫師與病患並改善經濟效益。我們的「品牌對學名藥」計畫(brand for generic program)預計將於今年夏季某個時間點推出。

  • Finally, another piece of good news, we are continuing to focus on improving patient access as well as improving our relationships with our channel partners. We have strengthened our managed-care organization with several key hires and we have been in active discussions with the payers to ensure continued patient coverage and access. I will address this point in more detail in a minute.

    最後,另一項好消息是,我們持續聚焦於改善病患可及性,同時也改善與通路合作夥伴的關係。我們透過數項關鍵招募強化了我們的受管醫療(managed-care)組織,並與付款方(payers)進行積極討論,以確保持續的病患給付覆蓋與可及性。我稍後會更詳細說明這一點。

  • During the past two weeks, we have already taken steps to restructure a number of our underperformance of our smaller businesses and we are taking steps to launch a broad-based cost reduction program. These actions will be partially offset by increased investment in key functions, such as financial reporting, public and government relations, and our managed-care organization. We are also currently exploring divestitures of non-core assets which will enhance our liquidity.

    在過去兩週內,我們已採取措施重整多項表現不佳的小型業務,並正著手推出一項廣泛的成本削減計畫。這些行動將部分被對關鍵職能的增加投資所抵銷,例如財務報導、公共與政府關係,以及我們的受管醫療組織。我們也正在評估出售非核心資產,以提升流動性。

  • Returning to market access. Maintaining US market access is critical for our entire portfolio and is critical to our success. To achieve this goal, we are investing more in rebates and building our organization's managed-care capability. The increases in rebates are due to more competitive pressure in response to our store price increases for our late life cycle products.

    回到市場可及性。維持美國市場可及性對我們整體產品組合至關重要,也是我們成功的關鍵。為達成此目標,我們將加大對回扣(rebates)的投入,並強化組織的受管醫療能力。回扣增加主要是因應我們對生命週期後段產品提高出廠價後所引發的更激烈競爭壓力。

  • Our US market access team, led by Sandy Loreaux, who joined us in January of this year, continues to have productive dialogue and negotiations concerning access for our entire portfolio with national health plans, PBMs and regional plans. These negotiations include our Part D and commercial bids for 2017, response to ad hoc therapeutic area reviews by payers, and requests for price inflation protection agreements.

    我們的美國市場可及性團隊由 Sandy Loreaux 領導,她於今年 1 月加入我們;團隊持續就我們整體產品組合的可及性,與全國性健康保險計畫、PBM(藥品福利管理機構)及區域性計畫進行富有成效的對話與談判。這些談判包括我們 2017 年的 Part D 與商業保險投標、回應付款方臨時性的治療領域審查,以及對價格通膨保護協議的要求。

  • Through these negotiations, beginning late last Fall this year, we have been able to maintain good coverage of commercialized for our key brands and franchises including dermatology, GI and ophthalmology franchise. We are working hard as a team, including the senior management team sitting here in this room today, to continue to improve our relationships with PBMs and health plans as well as access for our current portfolio and importantly, future launch products.

    透過這些談判,自去年秋末開始,我們已能維持已商業化之關鍵品牌與產品線的良好給付覆蓋,包括皮膚科、腸胃科(GI)與眼科產品線。我們以團隊方式全力以赴(包括今天在座的高階管理團隊),持續改善與 PBM 及健康保險計畫的關係,以及提升現有產品組合的可及性,更重要的是,為未來上市產品的可及性打下基礎。

  • We have made a great deal of progress and feel confident that we will improve our access in 2016 and 2017 and are laying the strong foundation for access to our expected new product launches. We are committed to engaging with these important customers more broadly across our organizations, building back trust through our actions and strengthening our capability to collaborate with them on initiatives involving our products.

    我們已取得顯著進展,並有信心在 2016 與 2017 年改善可及性,同時為預期的新產品上市建立堅實基礎。我們承諾在整個組織中更廣泛地與這些重要客戶互動,透過行動重建信任,並強化我們與其就涉及我們產品的各項計畫進行協作的能力。

  • Turning to our revised guidance. With the first quarter now updated, our new full year 2016 guidance as compared to what we previously reported, is expected to be $11 billion to $11.2 billion in revenue and adjusted EPS of $9.50 to $10.50. With our change to a different tax presentation, we expect to report adjusted EPS of $8.50 to $9.50.

    接著談我們修訂後的財測指引。隨著第一季數據更新,我們新的 2016 全年指引(相較先前公布)預期營收為 110 億至 112 億美元,調整後每股盈餘(adjusted EPS)為 9.50 至 10.50 美元。由於我們改採不同的稅務呈現方式,我們預期將報告的調整後 EPS 為 8.50 至 9.50 美元。

  • As we are moving away from adjusted cash flow from operations, we will now report an expected adjusted EBITDA number of $5.6 billion to $5.8 billion for 2016. As we look at the budget we prepared in December, several factors have changed our outlook for 2016.

    由於我們將不再使用「調整後營運現金流」作為指標,我們現在將改為報告 2016 年預期調整後 EBITDA 為 56 億至 58 億美元。回顧我們在 12 月編製的預算,有數項因素已改變我們對 2016 年的展望。

  • First, as Rob covered, the key one underperformance is expected to reduce adjusted EPS by $1 due to the higher-than-expected inventory reductions that transition from Philidor to Walgreens and the cancellation of almost all price increases. In addition, there has been negative impact from FX.

    首先,如 Rob 所述,關鍵的一項表現不如預期,預計將使調整後 EPS 減少 1 美元,原因是從 Philidor 轉換至 Walgreens 期間的庫存降幅高於預期,以及幾乎取消所有漲價。此外,匯率(FX)也帶來負面影響。

  • Next, we are taking a more conservative approach to our revenue assumptions and we are assuming lower growth rates for most of our franchises and geographies, including a slower rebound in dermatology, more modest growth in GI and underperformance in Women's Health, Commonwealth and Western Europe based on current expectations from economic factors and the current managed-care environment in the US.

    接著,我們對營收假設採取更保守的作法,並假設多數產品線與地區的成長率較低,包括皮膚科復甦較慢、腸胃科(GI)成長較溫和,以及女性健康、英聯邦(Commonwealth)與西歐業務表現不如預期;這些判斷係基於目前對經濟因素的預期,以及美國現行的受管醫療環境。

  • This conservatism is expected to reduce adjusted EPS of approximately $1 in 2016. As previously mentioned, any future price increases will be more modest and in line with industry practices and managed-care contracts. We have experienced increased competitive pressure at the payer level, resulting an increased rebates for access for our key growth products, like Jublia, and this accounts for a further $1 reduction from our budget in the Fall of last year.

    此一保守作法預計將使 2016 年調整後 EPS 約減少 1 美元。如先前所述,未來任何漲價幅度都將更為溫和,並與產業慣例及受管醫療合約一致。我們在付款方層面面臨更大的競爭壓力,導致為取得關鍵成長產品(如 Jublia)的可及性而提高回扣;相較去年秋季的預算,這又造成進一步減少 1 美元。

  • Other items that have reduced our outlook for 2016 include increased investments in select functions, FX headwinds and continued organizational distractions that will be cause of -- we estimate another $0.50 in 2016.

    其他降低我們 2016 年展望的項目包括:對特定職能的增加投資、匯率逆風,以及持續的組織分心因素;我們估計這些將在 2016 年再造成約 0.50 美元的影響。

  • Finally, the new tax presentation will reduce reported adjusted EPS by another $1, although it has no impact on either the actual taxes paid or the cash flow. To assist in the walk down from our revenue guidance in December to today, we have bucketed the main areas: GI, dermatology and neurology portfolios represent the bulk of the change due to the items already mentioned.

    最後,新的稅務呈現方式將使報告的調整後 EPS 再降低 1 美元,儘管這對實際繳納稅額或現金流皆無影響。為協助說明我們從 12 月的營收指引到今日的下修幅度,我們將主要變動領域分桶整理:腸胃科(GI)、皮膚科與神經科產品組合占變動的大宗,原因即為前述各項因素。

  • Underperformance in certain US business units accounts for approximately $300 million and ex-US, $200 million in revenue reduction. In terms of FX, we estimate that to be $110 million and the remaining $90 million covers the rest of the decrease.

    美國部分業務單位的表現不如預期,約占 3 億美元的營收減少;美國以外(ex-US)約占 2 億美元的營收減少。就匯率(FX)而言,我們估計影響約 1.10 億美元,其餘 9,000 萬美元涵蓋其他減少因素。

  • As we look out to the next several years, we wanted to highlight our growth expectations for our major business units. We expect double-digit growth from GI, Dendreon, dentistry, contact lenses and Women's Health over the next three years.

    展望未來數年,我們希望強調主要業務單位的成長預期。我們預期在未來三年,腸胃科(GI)、Dendreon、牙科、隱形眼鏡與女性健康將呈現雙位數成長。

  • Single-digit growth should be realized in dermatology, emerging markets in Europe, Asia, Latin America, US consumer, Ophthalmology Rx Canada, surgical and our aesthetics businesses. Finally, we expect our neurology and other Western Europe and US generic units to have flat to declining revenue growth over this three-year period.

    皮膚科、歐洲新興市場、亞洲、拉丁美洲、美國消費者業務、加拿大眼科處方藥(Ophthalmology Rx Canada)、外科以及醫美業務,預期可實現個位數成長。最後,我們預期神經科,以及其他西歐與美國學名藥業務,在這三年期間的營收成長將持平至下滑。

  • I do want to highlight that we do have some very exciting products that are either in the market and are new launches or we hope to get approved over the next year or so. We continue to be very excited about the prospects for Xifaxan and you've seen this continue the script growth.

    我也想特別指出,我們確實有一些非常令人振奮的產品,已在市場上且屬於新上市,或我們希望在未來一年左右取得核准。我們對 Xifaxan 的前景仍感到非常振奮,而你們也看到其處方量持續成長。

  • We're also excited about growth opportunities in a number of our emerging markets and are Ultra and Biotrue contact lens lines. Potential opportunities lie with several R&D projects such as Latanoprostene bunod for glaucoma, which we hope to get approved later this year; IDP-118, a topical for moderate to severe psoriasis, which we hope to get approved next year ; and Brodalumab for moderate to severe psoriasis, which we hope to get approved at the end of this year. A number of these growth products have $1 billion-plus potential.

    我們也對多個新興市場的成長機會,以及 Ultra 與 Biotrue 隱形眼鏡產品線感到振奮。潛在機會亦來自數個研發專案,例如用於青光眼的 Latanoprostene bunod(我們希望於今年稍晚取得核准);IDP-118(用於中度至重度乾癬的外用藥),我們希望於明年取得核准;以及用於中度至重度乾癬的 Brodalumab,我們希望於今年底取得核准。其中多項成長產品具備超過 10 億美元以上的潛力。

  • In terms of the next four quarters' guidance. With the weak results for the first quarter of 2016, we are providing a forward-look at the next fourth quarters, taking us through the first quarter of 2017.

    關於未來四個季度的指引。鑑於2016年第一季度的疲弱業績,我們提供對未來四個季度的前瞻展望,涵蓋至2017年第一季度。

  • On a roll-forward basis, we expect to realize between $11.6 billion and $11.8 billion in total revenues, and approximately $9.65 to $10.15 on adjusted EPS under the new tax reporting. We expect to realize approximately $6 billion in adjusted EBITDA over this time period. At this point, let me turn the call over to Linda LaGorga, our Treasurer, to discuss our balance sheet.

    以滾動基礎計算,我們預期總營收介於116億至118億美元之間,並在新的稅務申報口徑下,調整後每股盈餘(EPS)約為9.65至10.15美元。我們預期在此期間可實現約60億美元的調整後EBITDA。接下來,我把電話交給我們的財務主管(Treasurer)Linda LaGorga,請她說明我們的資產負債表。

  • - Treasurer

    - Treasurer

  • Thank you, Mike. First, focusing on our liquidity. We are comfortable with our current liquidity and expect strong cash flow generation from our business for the remainder of the year and beyond. Currently, we have approximately $1.2 billion of cash on hand, including the proceeds from recent revolver draws.

    謝謝你,Mike。首先,聚焦於我們的流動性。我們對目前的流動性水準感到安心,並預期今年剩餘期間及往後,我們的業務將持續帶來強勁的現金流。目前,我們手上約有12億美元現金,其中包含近期動用循環信貸(revolver)所取得的款項。

  • Our revolver is currently drawn at $1.45 billion. We most recently drew our revolver to fund cash timing related to ordinary course needs for operations, including anticipated upcoming debt payments.

    我們的循環信貸目前動用金額為14.5億美元。我們最近一次動用循環信貸,是為了因應與日常營運需求相關的現金時點安排,包括預期即將到期的債務付款。

  • We are expecting to close the sale of the Synergetics contract manufacturing business in the second quarter, providing additional cash. To date in the first quarter, we have completed the Sprout payment of $500 million in January and have repaid $405 million in term loans, including our Q1 $145 million mandatory amortization and $260 million in term loan maturities.

    我們預期將於第二季度完成出售Synergetics合約製造業務,帶來額外現金。截至第一季度目前為止,我們已於1月完成5億美元的Sprout付款,並已償還4.05億美元的定期貸款,其中包括第一季度1.45億美元的強制攤還,以及2.6億美元的定期貸款到期償還。

  • We have approximately $520 million of remaining mandatory term loan repayments in 2016, including $417 million of mandatory amortization and an estimated $100 million mandatory excess cash flow payment, which is an annual calculation under our credit agreement, which will be due at the end of March. We believe our term loan amortization and term loan and bond maturities in 2017 and 2018 are manageable.

    2016年我們尚有約5.2億美元的強制性定期貸款償還,包括4.17億美元的強制攤還,以及估計約1億美元的強制超額現金流付款;該付款係依我們的信貸協議按年度計算,並將於3月底到期。我們認為,2017年與2018年的定期貸款攤還,以及定期貸款與債券到期償還,均在可控範圍內。

  • Next, turning to some covenant highlights. Based on preliminary unaudited 2015 financial information and our 2016 guidance, we expect to remain in compliance with the financial maintenance covenants and our credit agreement for year-end 2015 and throughout 2016. There are no financial maintenance covenants in our indentures governing our bonds.

    接下來談一些契約條款(covenant)重點。根據初步未經審計的2015年財務資訊以及我們的2016年指引,我們預期在2015年年底及整個2016年期間,將持續符合信貸協議中的財務維持性契約條款。規範我們債券的契約(indentures)中,並無財務維持性契約條款。

  • Our credit agreement includes two maintenance covenants, a secured leverage ratio and an interest coverage ratio. For the year-end 2015, we expect our secured leverage ratio to be approximately 2.1 times and our interest coverage ratio to be approximately 3.3 times, both within credit agreement requirements.

    我們的信貸協議包含兩項維持性契約條款:擔保槓桿比率(secured leverage ratio)與利息保障倍數(interest coverage ratio)。以2015年年底而言,我們預期擔保槓桿比率約為2.1倍、利息保障倍數約為3.3倍,兩者皆符合信貸協議要求。

  • Our net leverage to pro forma adjusted EBITDA for the credit agreement expected to be approximately 5.8 times at year-end 2015. A couple of key factors contributed to the increase of our Q4 leverage ratio relative to our Q3 leverage ratio. First, for our last 12 months adjusted EBITDA per our credit agreement, we no longer have the benefit of the Allergan gain from Q4 2014 of approximately $287 million.

    依信貸協議口徑計算,我們的淨槓桿(net leverage)相對於備考調整後EBITDA,預期在2015年年底約為5.8倍。有幾個關鍵因素導致我們第四季槓桿比率相較第三季上升。首先,就依信貸協議計算的過去12個月調整後EBITDA而言,我們不再享有2014年第四季約2.87億美元的Allergan處分收益所帶來的挹注。

  • Second, also for our adjusted EBITDA per our credit agreement, our Q4 adjusted EBITDA was impacted by $100 million by our Broda transaction which is treated as cash IPR&D and reduces adjusted EBITDA in our credit agreement. Based on our 2016 guidance, we expect our net leverage to pro forma adjusted EBITDA per our credit agreement to be approximately 5 times by year-end 2016.

    第二,同樣就依信貸協議計算的調整後EBITDA而言,我們第四季的調整後EBITDA受到Broda交易的1億美元影響;該項在信貸協議中被視為現金型在研發(cash IPR&D),因此會降低信貸協議口徑下的調整後EBITDA。根據我們的2016年指引,我們預期依信貸協議口徑計算的淨槓桿相對於備考調整後EBITDA,至2016年年底約為5倍。

  • Now moving to some covenant highlights related to financial statement reporting. Both our credit agreement and our bond indenture contain financial reporting requirements which are impacted by the delay in the filing of our 10-K.

    現在談一些與財務報表申報相關的契約條款重點。我們的信貸協議與債券契約均包含財務申報要求,而這些要求會受到我們延遲提交10-K的影響。

  • If we do not file our 10-K by March 30, a default will occur under our credit agreement. We will have 30 days, or until April 29, to cure this default by filing our 10-K. If our 10-K has not been filed before March 16, a breach of reporting covenant occurs under our bond indentures.

    若我們未能在3月30日前提交10-K,將構成我們信貸協議下的違約。我們將有30天(即至4月29日)可透過提交10-K來補救該違約。若我們的10-K在3月16日前仍未提交,則將構成我們債券契約下的申報契約條款違反。

  • At any time after this breach, the trustee or holders of at least 25% of any series of notes may deliver a notice of default. From receipt of this notice, we would have 60 days to file our 10-K and that's to cure the default. While the failure to file the 10-K before March 16 does not have any immediate implications under our bond indentures, it does result in cross-default under our credit agreement.

    在發生該違反後的任何時間,受託人或任何一個系列票據中至少25%的持有人,均可送達違約通知。自收到該通知起,我們將有60天可提交10-K,以補救該違約。雖然未能在3月16日前提交10-K在我們的債券契約下不會產生任何立即影響,但會導致我們信貸協議下的交叉違約(cross-default)。

  • The credit agreement lenders do not immediately have the right to accelerate on account of this cross-default but our ability to borrow under the revolver is restricted while the default continues. We now -- next week, we intend to launch an amendment process with our lenders to waive this cross-default and also to extend the time period for delivery of our 10-K and our Q1 10-Q.

    信貸協議的貸方並不會因該交叉違約而立即享有加速到期(accelerate)的權利,但在違約持續期間,我們在循環信貸項下的借款能力將受到限制。我們現在——預計在下週——打算與貸方啟動修訂程序,以豁免該交叉違約,並延長我們提交10-K及第一季度10-Q的期限。

  • Moving now to cash available for debt repayment and other purposes. One of our key 2016 priorities is to focus on our balance sheet. We remain committed to using the vast majority of our cash flow to pay down debt. At our Investor Day in December, we said we expect to pay down more than $2.25 billion of permanent debt in 2016.

    接著談可用於償債及其他用途的現金。我們2016年的一項關鍵優先事項是聚焦於資產負債表。我們仍致力於將絕大部分現金流用於償還債務。在12月的投資人日上,我們表示預期在2016年償還超過22.5億美元的永久性債務(permanent debt)。

  • Based on our revised guidance, we remain committed to debt repayment and now expect to pay down more than $1.7 billion of permanent debt this year. Relative to our prior guidance, the reduction in cash available for debt repayment and other purposes is less than the reduction in adjusted EBITDA. This is primarily due to less use of cash from working cap and less taxes based on our reduced sales expectations.

    根據我們修訂後的指引,我們仍致力於償債,並且現在預期今年將償還超過17億美元的永久性債務。相較於先前指引,可用於償債及其他用途的現金減少幅度,小於調整後EBITDA的減少幅度。這主要是因為營運資金占用的現金較少,以及在銷售預期下修的情況下稅負較低。

  • I will now turn it back over to Mike.

    我現在把話交回給Mike。

  • - CEO

    - CEO

  • We have received several key questions from many of you so we thought we would address a number of them during our presentation. First, our approach to pricing. We have already committed to reducing pricing on our brand-new dermatology and ophthalmology products within the Walgreens' portfolio, on average, 10%.

    我們收到各位提出的幾個關鍵問題,因此我們想在簡報中回應其中一些。首先,我們的定價作法。我們已承諾,對Walgreens產品組合中我們全新推出的皮膚科與眼科產品,平均降價10%。

  • This price reduction is on WAC and will impact and will be taken across all channels, not just Walgreens. Other price increases will be modest and in line with market and payer contracts.

    這次降價是針對WAC(批發採購成本),並將影響且會適用於所有通路,而不僅限於Walgreens。其他價格調整將會溫和,並與市場及付款方合約保持一致。

  • In terms of divestitures, as a public company, we continue to review our assets in order to maximize shareholder value. We have no current plans to divest any major platform; however, we will continue to look at non-strategic assets and make appropriate decisions.

    就資產出售而言,作為一家上市公司,我們持續檢視資產以最大化股東價值。我們目前沒有出售任何主要平台的計畫;然而,我們將持續評估非策略性資產並作出適當決策。

  • The ad hoc committee. The ad hoc committee has provided the following statement. I quote -- the ad hoc committee has completed a substantial amount of work related to Philidor and certain accounting and financial reporting matters. The committee and its advisors are working diligently and hope to complete the committee's work in the near future -- end quote. As noted, in light of the ongoing nature of these matters, we will not be providing any further comments on the ad hoc committee at this time.

    臨時委員會(ad hoc committee)。臨時委員會發表了以下聲明。我引用——臨時委員會已就Philidor以及若干會計與財務申報事項完成了大量工作。委員會及其顧問正勤勉工作,並希望在不久的將來完成委員會的工作——引述結束。如前所述,鑑於這些事項仍在進行中,我們目前不會就臨時委員會提供進一步評論。

  • Finally, we have a subject to several ongoing investigations. These include investigations by the US Attorney's Office for Massachusetts and the Southern District of New York, the SEC and Congress. We are cooperating in these investigations and have provided and will be providing documents, information and testimony in these various investigations, whether pursuant to subpoenas or otherwise.

    最後,我們正面臨數項持續進行的調查。其中包括美國麻薩諸塞州聯邦檢察官辦公室與紐約南區聯邦檢察官辦公室、SEC以及國會的調查。我們正配合這些調查,並已提供且將持續提供文件、資訊與證詞,不論是依傳票要求或以其他方式。

  • We're also subject to shareholder litigation in both the United States and Canada, which we intend to defend vigorously. Given the ongoing nature of the investigations and litigation, we do not intend to comment further at this time.

    我們在美國與加拿大亦面臨股東訴訟,我們打算積極應訴。鑑於調查與訴訟仍在進行中,我們目前不打算進一步評論。

  • So in summary, our business is not operating on all cylinders but we and I are committed to getting it back on track. We have a set of terrific products and brands and a loyal set of physicians, patients and customers.

    總結來說,我們的業務尚未全速運轉,但我們以及我本人都致力於讓業務重回正軌。我們擁有一系列出色的產品與品牌,以及忠誠的醫師、病患與客戶群。

  • Through both revenue enhancement and cost reduction, we are confident that we can and, again, will be able to begin to deliver the cash flows our shareholders and debt holders are accustomed to. With that -- with this, I will open the line to questions.

    透過提升營收與降低成本,我們有信心能夠、而且也將能夠開始交付股東與債權人所習慣的現金流。那麼——在此,我將開放提問。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Louise Chen, Guggenheim

    Louise Chen,Guggenheim

  • - Analyst

    - Analyst

  • Hi. Thanks for taking my questions.

    嗨。謝謝讓我提問。

  • I had a few here. So first question I had was on your weak GI sales in the fourth quarter related to Walgreens. I was wondering if you could give more color there since our focus was on derm, as you mentioned before, on Walgreens. There was only 15 days left in the quarter and there was already some destocking from the Salix deal.

    我這裡有幾個問題。第一個問題是關於你們第四季與 Walgreens 相關的腸胃(GI)銷售疲弱。我想知道你們能否提供更多細節,因為如你先前提到,我們的焦點一直在 Walgreens 的皮膚科(derm)。該季度只剩 15 天,而且 Salix 交易已經出現一些去庫存(destocking)。

  • And then second thing, I was wondering if you could talk about the changes in your managed care contracts that you mentioned in your press release. And the last thing, maybe more color on the gross margin and how we think about gross to net for the Walgreens drugs?

    第二,我想請你談談你們在新聞稿中提到的醫療保險管理(managed care)合約變更。最後,能否再多談一些毛利率,以及我們該如何看待 Walgreens 藥品的毛額到淨額(gross-to-net)?

  • Thanks.

    謝謝。

  • - CEO

    - CEO

  • Sure. Let me talk about the weak GI sales. I'll have Anne Whitaker talk about the changes in managed care. I will come back and address the Walgreens economics.

    當然。我先談談腸胃(GI)銷售疲弱的部分。我會請 Anne Whitaker 談談醫療保險管理(managed care)的變更。之後我再回來說明 Walgreens 的經濟條件。

  • So at the end of the fourth quarter, a number of orders were canceled of Salix products. This was sort of at least -- we were told, based on reducing inventories in some distributors and some retailers, there was a negative reaction initially to the Walgreens program and some aspects of it. The managed care team has done a terrific job working with the payers to modify the Walgreens program to make it acceptable and so we feel good about that.

    在第四季末,有一些 Salix 產品的訂單被取消。至少我們被告知,這是因為部分經銷商與零售商在降低庫存;此外,市場對 Walgreens 計畫及其某些面向一開始也有負面反應。醫療保險管理團隊在與付款方合作、調整 Walgreens 計畫使其可被接受方面做得非常出色,因此我們對此感到樂觀。

  • You can notice the script trends in the GI franchise will continue to be very strong so we think that will even out over time.

    你可以注意到,腸胃(GI)產品線的處方趨勢仍將非常強勁,因此我們認為隨時間推移會逐步拉平。

  • Anne, managed care?

    Anne,醫療保險管理?

  • - Company Group Chairman

    - Company Group Chairman

  • Sure. As Mike mentioned, with regard to our contracting since last Fall, we have been involved with submitting our bids for the Part D program for 2017. We've been going through the process of renewing contracts for 2017 and some of those, we have -- did extensions for 2016, even last Fall.

    好的。如 Mike 提到的,關於我們自去年秋季以來的簽約(contracting),我們一直在提交 2017 年 Part D 計畫的投標。我們也在進行 2017 年合約續約流程,其中一些合約我們在去年秋季就已為 2016 年做了延長。

  • Payers, on a routine basis each quarter, pick categories that they do reviews of; therapeutic areas, they do reviews of and so we've been responding to some of those reviews. Dermatology is one of those reviews that many of the payers are undertaking, because as they look back and their clients look back at last year, dermatology was one of the biggest trend drivers for them. So they've picked that category to focus on this year.

    付款方通常每一季都會例行挑選一些類別進行審查;也就是他們會審查某些治療領域,因此我們一直在回應其中一些審查。皮膚科是許多付款方正在進行審查的領域之一,因為他們回顧去年、以及其客戶回顧去年時,皮膚科是最大的趨勢驅動因素之一。因此他們今年選擇聚焦在這個類別。

  • We also have been engaging in discussions as part of the process of our contracting in these ad hoc reviews on price inflation protection. We've had price protection agreements in place with payers. We've been negotiating through that process on specific rates, and those range depending on the volume and the particular product.

    此外,作為我們簽約流程的一部分,在這些臨時(ad hoc)審查中,我們也就價格通膨保護(price inflation protection)進行討論。我們與付款方之間原本就有價格保護協議。我們正在就特定比率進行協商,而這些比率會依據用量與特定產品而有所不同。

  • So I will just echo what Mike said. I feel very good about the progress that we are making as a Company, with really rebuilding our relationships with the payers and working through this negotiations process. And I think we're building a strong team here at Valeant with some of the new folks that we have brought in. We have brought a number of them in over the past few months. To really beef up that capability and I'm confident we have good prospects for laying a firm foundation for the launch products that Mike mentioned as well.

    所以我只是呼應 Mike 的說法。我對公司目前的進展感到非常樂觀,尤其是在重建與付款方的關係、並推進這個談判流程方面。我認為我們也正在 Valeant 建立一支強大的團隊,包含我們引進的一些新成員。過去幾個月我們引進了不少人。以真正強化這項能力;我也有信心,我們在為 Mike 也提到的上市產品奠定穩固基礎方面,前景良好。

  • - CEO

    - CEO

  • Let me address sort of the way the Walgreens economics work, and thus the gross margins, gross to net, et cetera. The way the contract is negotiated, it's an activity-based fee that we pay Walgreens. What I mean by activity-based is that they get paid different amounts based on different scripts.

    我來說明一下 Walgreens 的經濟條件如何運作,因而影響毛利率、毛額到淨額(gross-to-net)等等。合約的談判方式是:我們支付 Walgreens 一筆以活動為基礎(activity-based)的費用。我所謂以活動為基礎,是指他們會依不同處方(scripts)獲得不同金額的報酬。

  • If it's a cash paid scripts, it's one fee; if they adjudicate insurance, we pay a little bit more. If they do a prior auth, we do a little bit more; if they do work around refills, we pay a little bit more. So it's an activity-based fee.

    如果是自費處方(cash paid scripts),是一種費用;如果他們進行保險理賠判定(adjudicate insurance),我們會多付一些。如果他們做事前授權(prior auth),我們再多付一些;如果他們處理續配(refills)相關工作,我們也會多付一些。因此這是一種以活動為基礎的費用。

  • The early experience with Walgreens compared to Philidor is that there is more cash pay than what we had -- what we saw with Philidor, but that's largely a function of prior auths. That's not a capability that Walgreens currently has, so what we'll be doing is using a third-party. We agreed with them last week. We use a third-party until they either build that capability or we'll continue to use a third party.

    與 Philidor 相比,Walgreens 的早期經驗顯示自費比例更高;但這在很大程度上是事前授權(prior auth)的因素所致。這不是 Walgreens 目前具備的能力,因此我們將使用第三方。我們上週已與他們達成一致。我們會使用第三方,直到他們建立該能力,或是我們將持續使用第三方。

  • We expect the economics, as I mentioned, to improve over time. What we've been focused primarily on is volume. The key is to get scripts, and through Walgreens and to make sure the physicians have a good alternative to Philidor and many physicians really like the Philidor program.

    如我提到的,我們預期經濟條件會隨時間改善。我們主要聚焦的是量(volume)。關鍵是取得處方量,透過 Walgreens,並確保醫師有一個良好的 Philidor 替代方案;而許多醫師確實很喜歡 Philidor 的計畫。

  • And again, as I mentioned, well over 90% of the physicians that were using Philidor are currently using Walgreens, but perhaps more importantly is the number of new doctors that, given Walgreens' great reputation and national brand, are now using Walgreens that weren't using Philidor.

    再者,如我提到的,先前使用 Philidor 的醫師中,遠超過 90% 目前正在使用 Walgreens;但或許更重要的是,因為 Walgreens 優良的聲譽與全國性品牌,有更多原本未使用 Philidor 的新醫師現在開始使用 Walgreens。

  • So we've been focused on getting our physicians comfortable with Walgreens, and then we will continue to tweak the program with Walgreens to better serve patients and doctors and also improve the economics to both companies.

    因此,我們一直著重讓醫師對 Walgreens 感到安心;接著我們會持續與 Walgreens 微調該計畫,以更好地服務病患與醫師,同時也改善兩家公司的經濟效益。

  • Next question.

    下一個問題。

  • Operator

    Operator

  • Annabel Samimy, Stifel.

    Annabel Samimy,Stifel。

  • - Analyst

    - Analyst

  • Thanks for taking my question.

    謝謝讓我提問。

  • First, I want to go back to the adjustments that you made for GI with regard to the Walgreens program. Originally, it was supposed to be only derm and ophthalmology, so can you just explain a little bit more what the issues were that they were upset with and what specific changes you made for GI within Walgreens, because originally, it was not going to be included.

    首先,我想回到你們針對 Walgreens 計畫對腸胃(GI)所做的調整。一開始原本應該只涵蓋皮膚科與眼科,所以你能否再多解釋一下,他們不滿的點是什麼,以及你們在 Walgreens 內針對腸胃(GI)做了哪些具體變更?因為原本是沒有要納入的。

  • Also there were a lot of inventory changes within GI in the first quarter and I guess in the past, it was thought that the Salix inventories were going to be -- the destocking for Salix was going to be finished at the of 2015, so is this destocking now related to those cancelled orders and that continues into the first quarter. And do you see more normal growth after that second quarter forward? And then finally on the divestitures, can you just detail what businesses you generally believe are non-core to Valeant and how much that might be able to contribute to debt paydown going forward?

    另外,第一季腸胃(GI)領域有很多庫存變動;而我想過去的看法是 Salix 的庫存——Salix 的去庫存(destocking)應該在 2015 年底就會結束,所以現在這次去庫存是否與那些被取消的訂單有關,並且延續到第一季?而在那之後,從第二季起你是否看到更正常的成長?最後關於資產剝離(divestitures),你能否說明一下你們一般認為哪些業務對 Valeant 而言屬於非核心(non-core),以及這些可能在未來能為償還債務(debt paydown)貢獻多少?

  • Thank you.

    謝謝。

  • - CEO

    - CEO

  • So, first of all, to clarify that is -- GI is not part of the Walgreens program. But I think that maybe we weren't clear on that. Therefore, it did have -- the announcement with Walgreens did have an impact on GI, because I think just like you probably assumed GI was going to be part of it, so did other players.

    所以,首先澄清一下——GI 並不是 Walgreens 計畫的一部分。但我想我們可能沒有把這點講清楚。因此,與 Walgreens 的公告確實對 GI 造成了影響,因為我想就像你可能以為 GI 會包含在其中一樣,其他參與者也這麼認為。

  • We probably -- we should take responsibility, I will take responsibility, we probably did not communicate the Walgreens program as well as we could have to payers and channel partners. We've done that. They had some suggestions in terms of how we can modify it that they get more comfortable. I'm not going to go into the specifics of those.

    我們可能——我們應該承擔責任,我願意承擔責任;我們可能沒有把 Walgreens 計畫向付款方與通路夥伴溝通得像我們本可以做得那麼好。我們已經做了相關溝通。他們就我們如何調整以讓他們更安心提出了一些建議。我不會深入說明那些細節。

  • We have accepted their suggestions. Walgreens and us have -- we've been working well together so the comfort level is much higher now. So, but GI is not part of the Walgreens program. In December, we -- I think we tried to be clear and if we weren't clear, I apologize but in terms of destocking, we talked about destocking taking place, both in the fourth quarter and first quarter.

    我們已接受他們的建議。Walgreens 與我們——我們一直合作得很順利,所以現在的安心程度高很多。不過,GI 並不是 Walgreens 計畫的一部分。在 12 月,我們——我想我們試著講清楚;如果我們沒有講清楚,我致歉。但就去化庫存(destocking)而言,我們談到去化庫存會在第四季與第一季都發生。

  • For example, we didn't turn on the Walgreens program until January 15. At that point, all the inventory in Walgreens that they were carrying converted to consignment. So by definition, there was a destocking element. We do expect that both the dermatology and ophthalmology franchises will return to growth in the second quarter once the destocking will occur.

    例如,我們直到 1 月 15 日才啟動 Walgreens 計畫。在那個時間點,Walgreens 所持有的所有庫存都轉為寄售(consignment)。所以按定義來說,確實存在去化庫存的因素。我們預期,一旦去化庫存完成,皮膚科與眼科兩大事業群將在第二季恢復成長。

  • We were unable to measure precisely how much would happen in fourth quarter and how much would happen in first quarter, so we gave our best estimate in December. Turns out a little bit more happened in the fourth quarter. We've given you our first-quarter estimates, but going forward, in the second quarter, we expect that destocking to occur.

    我們無法精準衡量第四季會發生多少、第一季會發生多少,所以我們在 12 月給出了我們的最佳估計。結果是第四季發生的比預期多一些。我們已提供你們第一季的估計;但往後看,在第二季我們預期去化庫存將會完成。

  • In terms of the divestitures of non-core, we do not want to give specifics. We are in discussions with other parties. We have confidentially around that. But it will be things like Synergetics where when we bought Synergetics, the part that we were interested in and that was strategic was the ophthalmology versus the franchise. What we sold was a contract manufacturing and surgical neurology, which is not an area that we compete in. We had no sales force and rather than build a sales force and get into an entirely new area, we ended up selling it to a company that was in that area.

    至於非核心資產的剝離,我們不想提供具體細節。我們正在與其他方討論。這方面我們有保密要求。但會是像 Synergetics 這類的項目:當我們收購 Synergetics 時,我們感興趣且具策略性的部分是眼科相關的事業。我們出售的是合約製造與外科神經學業務,這並不是我們競爭的領域。我們沒有銷售團隊;與其建立銷售團隊並進入一個全新的領域,我們最後把它賣給了在該領域已有布局的公司。

  • Then if you look the net price, we ended up paying for the ophthalmology assets, it was less than $[15] million. So that it is an example of a non-strategic asset that there we were able to monetize. Again, we will only do this if we believe that the cash flows that we would expect from our franchise are less than what someone's willing to pay for the assets. Next question, please.

    如果你看淨價格,我們最後為眼科資產所支付的金額不到 $[15] 百萬美元。所以這是一個我們能夠變現的非策略性資產例子。同樣地,只有在我們認為自家事業群預期帶來的現金流低於他人願意為這些資產支付的價格時,我們才會這麼做。下一個問題,請。

  • Operator

    Operator

  • Marc Goodman, UBS. Mr. Goodman.

    UBS 的 Marc Goodman。Goodman 先生。

  • - Analyst

    - Analyst

  • Hi, Mike. A couple things. Number one, I didn't see you talk about the emerging markets at all. Can you talk a little bit about what's happening there? And, obviously, those markets have weakened a little bit. You didn't really talk about them.

    嗨,Mike。有幾點。第一,我沒有看到你提到新興市場。你能談一下那邊發生了什麼嗎?而且,很明顯,那些市場有些走弱。你其實沒有怎麼談到它們。

  • Second, what happened with Solta and Obagi relative to how you were thinking about this two or three months ago? Did these businesses just slow down just dramatically, or is there something going on there?

    第二,Solta 和 Obagi 相較於你們兩三個月前的想法,發生了什麼?這些業務是突然大幅放緩,還是那邊有其他狀況?

  • Third thing is, can you give us an update on the contact lens capacity? I know this is important to you as you ramp up capacity, are you going to be able to sell your lenses just in the US, or is the new lens still just going -- is it still just going in the US? Are you able to sell it in Europe this year? I'm just trying to get a sense of how much capacity is ramping up?

    第三,你能更新一下隱形眼鏡的產能嗎?我知道當你們提升產能時這對你們很重要;你們是否只能在美國銷售鏡片,還是新鏡片仍然——是否仍然只在美國銷售?你們今年能在歐洲銷售嗎?我只是想了解產能提升的幅度有多大?

  • And then last on tax, can you just explain to us, like, why the change in tax now? Thank you.

    最後關於稅務,你能跟我們解釋一下,例如,為什麼現在稅率會有變化嗎?謝謝。

  • - CEO

    - CEO

  • Sure. So, emerging markets. Two things are happening in emerging markets. One, FX continues to work against us, which in a sense, doesn't necessarily have an impact on market demand, but does have an impact in terms of gross margins, because as you guys know, most of the API is sourced either from the US or Europe.

    當然。關於新興市場。新興市場有兩件事正在發生。第一,外匯(FX)持續對我們不利;某種程度上,這未必會影響市場需求,但會影響毛利率,因為如各位所知,多數 API(活性藥物成分)來源不是美國就是歐洲。

  • So there -- it's either Euro-denominated or dollar-denominated, and as the dollar continues to strengthen relative to the emerging markets, it puts pressure on the profitability. In terms of -- it's sort of by market. Russia continues to be a challenge. Some of the Eastern European markets are -- continue to be influenced by Europe and they continue to be challenged.

    所以——要嘛以歐元計價,要嘛以美元計價;而隨著美元相對新興市場貨幣持續走強,會對獲利能力造成壓力。至於——這有點因市場而異。俄羅斯仍然是一項挑戰。一些東歐市場——仍持續受到歐洲影響,也仍然面臨挑戰。

  • There are some bright spots -- our Middle East, and in particular, our Amoun acquisition continues to grow very robustly. Mexican continues to be a strong market for us. And Asia continues to do very well. In particular, China, which is a real strength for us. So I think emerging markets will always be a mix. I think one of the advantages of being in many of the emerging markets is there's always some that are outperforming and some that are not performing.

    也有一些亮點——我們的中東,尤其是我們收購的 Amoun,持續非常強勁地成長。墨西哥對我們而言仍是強勁市場。而亞洲持續表現很好。尤其是中國,這是我們真正的強項。所以我認為新興市場永遠會是混合的表現。我想在許多新興市場都有布局的一個優勢是:總會有一些市場表現超出預期,也會有一些市場表現不佳。

  • So we do continue to expect to have high single-digit growth in the emerging markets. But in terms of actual dollars, as FX continues to strengthen, both on the revenue side, the dollars will -- it will be depressed and then in terms of profitability, because of the API issue, it will continue to hurt us if the dollar stays where it is or it continues to strengthen versus where we were in December.

    因此,我們仍預期新興市場將維持高個位數成長。但就實際美元金額而言,隨著外匯持續走強,在營收端,以美元計的數字將——會被壓低;而在獲利端,因為 API 的因素,如果美元維持在目前水準,或相較於我們 12 月時的水準繼續走強,將會持續對我們不利。

  • Maybe I'll have Ari talk a little bit about Solta and Obagi, which he just took over recently, and maybe he can also talk about the Ultra capacity. And then Rob, maybe you can address the tax issues.

    也許我請 Ari 談一下 Solta 和 Obagi;他最近才接手,或許他也可以談談 Ultra 的產能。然後 Rob,也許你可以回應稅務議題。

  • - Company Group Chairman

    - Company Group Chairman

  • Yes, Marc, on the contact lens capacity, we've said before that we will have three to four lines of Ultra up and running this year. We're out of capacity through Q1 and Q2, but we have capacity coming online Q3 and Q4. So we actually are going to be expanding sales into Europe and other parts of Asia, and we are fortunate to have additional capacity on the sphericals. We've also launched a multi-focal and that's gaining a lot of traction in the US.

    好的,Marc,關於隱形眼鏡產能,我們之前說過,今年會有三到四條 Ultra 產線啟動並運轉。我們在第一季與第二季都處於滿載、沒有多餘產能,但第三季與第四季會有產能上線。因此,我們實際上將把銷售擴展到歐洲及亞洲其他地區;而我們也很幸運在球面鏡片(sphericals)方面有額外產能。我們也推出了多焦點(multi-focal)產品,在美國獲得很大的市場動能。

  • So there will be a good amount of Ultra that will be able to expand outside the US in Q3 and Q4, while still doubling sales of Ultra in the US this year. On Biotrue, we're adding several lines. There we're still tight for capacity; the demand has been very strong in North America and elsewhere in the world. So there, it's really catch-up, but we're investing heavily in capacity.

    因此,在第三季與第四季,會有相當數量的 Ultra 能夠擴展到美國以外市場,同時今年在美國仍可將 Ultra 的銷售翻倍。至於 Biotrue,我們正在新增數條產線。那邊我們的產能仍然吃緊;北美以及全球其他地區的需求一直非常強勁。所以那裡主要是在追趕需求,但我們正在大幅投資擴充產能。

  • Turning to Solta and Obagi. Obagi is a nicely profitable business. We were at the American Academy of Dermatology last week, spent several days there talking to many key opinion leaders across medical dermatology and anesthetics, and we actually have a lot of public suggestions and encouragement across both of these businesses.

    接著談 Solta 與 Obagi。Obagi 是一個獲利相當不錯的事業。我們上週參加了美國皮膚科醫學會(AAD),在那裡待了好幾天,與醫學皮膚科與麻醉領域的許多關鍵意見領袖交流,實際上我們也在這兩個事業上獲得了不少公開的建議與鼓勵。

  • So Obagi is profitable. I think what we need to do a better job on is expanding our focus across the national accounts, bolstering leadership and basic sales execution. We have a terrific team across marketing and sales. I think we probably have not put enough focus against this business. This is a great set of products with a great brand and we think we could do a better job and we are accountable for that and we'll do the job that we need to.

    所以 Obagi 是獲利的。我認為我們需要做得更好的是:擴大我們在全國性客戶(national accounts)上的投入、強化領導力,以及基本的銷售執行。我們在行銷與銷售方面有一支非常出色的團隊。我想我們可能沒有在這個事業上投入足夠的關注。這是一組很棒的產品、很棒的品牌,我們認為可以做得更好;我們對此負責,也會把該做的工作做好。

  • Likewise on Solta, we had our machines on display at the AAD. We actually had a good number sales there. Again, we have a terrific team with Vlad, who is well-known in the business. There we have work to do. We have to restore this business to profitability. The good news is we have a new Thermage system coming online. We have also recently launched the pelo hair loss -- hair removal system, which again, we expect to do well in North America.

    同樣地,在 Solta 方面,我們在 AAD 展示了我們的設備。我們實際上也在那裡完成了相當數量的銷售。同樣地,我們有一支很棒的團隊,由在業界頗具知名度的 Vlad 領軍。但我們仍有工作要做。我們必須讓這個事業恢復獲利。好消息是,我們有一套新的 Thermage 系統即將上線。我們最近也推出了 pelo 掉髮——除毛系統;同樣地,我們預期它在北美會有不錯的表現。

  • But we also have representatives from the Latin American region and we're going to be setting this system across the world. There again, it's just restoring profitability, getting focused in the field, improving sales execution and again, we're -- we believe we have a good set of products and it's our job to make sure that we support the appropriate demand in the field.

    不過我們也有來自拉丁美洲地區的代表,我們將在全球推廣這套系統。同樣地,重點就是恢復獲利、讓前線更聚焦、提升銷售執行;而且我們——我們相信我們有一套很好的產品,確保在前線支援適當的需求是我們的責任。

  • - CFO

    - CFO

  • Hey, Mark, on the tax issue. We have had ongoing dialogue with the SEC. It has been quite productive from our perspective. We think this is an appropriate presentation. I point out that it has no impact on the cash flow or actual taxes paid.

    嗨,Mark,關於稅務議題。我們一直與美國證券交易委員會(SEC)保持對話。從我們的角度來看,這些對話相當有成效。我們認為這樣的呈現方式是適當的。我要指出的是,這對現金流或實際繳納的稅額沒有任何影響。

  • - CEO

    - CEO

  • Next question, please.

    請下一題。

  • Operator

    Operator

  • Andrew Finkelstein, Susquehanna.

    Susquehanna 的 Andrew Finkelstein。

  • - Analyst

    - Analyst

  • Good morning. Thanks for taking the question.

    早安。謝謝讓我提問。

  • Could you talk a bit more about the cash flow guidance for the year and some of the level of clarity around the individual moving parts, given both the operational factors with destocking and uncertainties on pricing, as well as the additional adjustments? You talk about restructuring and the other things that don't affect the non-GAAP P&L.

    能否再多談一些今年的現金流指引,以及在各個組成項目上的可見度?考量到去庫存(destocking)等營運因素與定價不確定性,以及額外調整項。你們提到重組以及其他不影響非 GAAP 損益表(P&L)的事項。

  • What is the level of confidence in achieving that level of cash generation in 2016? And then as you approach these payer negotiations particularly for 2017, can you talk a little bit more about the process, in particular, to what extent are you able to leverage your portfolio of products in trying to maintain access for some of the categories that have been more of a focus for payers to show savings to their clients?

    對於在 2016 年達成該水準現金創造能力,你們的信心程度如何?另外,當你們接近這些付款方(payer)談判、特別是針對 2017 年時,能否再多談一些流程?尤其是,你們在嘗試維持某些較受付款方關注、需要向其客戶展現節省效益的品類之可近性(access)時,能在多大程度上運用你們的產品組合來取得槓桿?

  • Thanks very much.

    非常感謝。

  • - CEO

    - CEO

  • Sure. I will take a shot at these, but I'm going to ask Linda and Anne and to expand if I miss anything. In terms of cash flow guidance, we've tried to be conservative. You can do the math. You can take our guidance and do the arithmetic and see how much cash flow we -- that guidance levels.

    當然。我先嘗試回答這些問題,但如果我漏了什麼,我會請 Linda 和 Anne 補充。就現金流指引而言,我們試著採取保守作法。你可以自己算。你可以用我們的指引做算術,看看我們——在該指引水準下的現金流是多少。

  • And we've tried to -- I think we feel quite comfortable at the $1.7 billion that we now have good line of sight on price for our entire portfolio for the year. Managed care, we have good sight, line of sight. Most of these negotiations have either been completed in terms of managed care or close to completion. We're not embarking on the negotiations. We're finalizing them and we're in final rounds and they've been very constructive.

    而我們也試著——我想我們對目前的 17 億美元相當有把握,因為我們現在對今年整個產品組合的價格有很好的可見度。在管理式醫療(managed care)方面,我們也有很好的可見度。這些談判大多已完成,或接近完成。我們不是才要開始談判。我們是在收尾,正進入最後幾輪,而且進展非常具建設性。

  • We've done a lot of listening to the payers. We have tried to be very accommodating and Anne and her team has just done a terrific job changing the momentum from a managed care standpoint. And as we talked about the whole Company is involved and in on this. It's moved from sign that was lowered out in the organization to the -- with Anne's joining the Company to a top-level priority for the Company.

    我們做了大量傾聽付款方的工作。我們努力以非常配合的方式處理,而 Anne 和她的團隊在管理式醫療面向上,確實把動能扭轉得非常出色。如同我們談到的,整家公司都參與其中、也都投入。在 Anne 加入公司之前,這在組織內只是被淡化的一個訊號;但隨著 Anne 加入公司,這已成為公司最高層級的優先事項。

  • That's the highest level. I know, Linda, any other comments on the cash flow? And then Anne --

    這是最高層級。Linda,你對現金流還有其他補充嗎?然後 Anne——

  • - Analyst

    - Analyst

  • Just to be clear, if I can interrupt, when you're talking about the visibility, you're talking about visibility for 2017?

    我插問一下,為了釐清:你提到的可見度,是指 2017 年的可見度嗎?

  • - CEO

    - CEO

  • Correct. 2016 and 2017.

    沒錯。2016 年和 2017 年。

  • - Treasurer

    - Treasurer

  • So to make a couple of quick comments, you asked about cash restructuring. This is our estimate at this time. We had previously estimated $200 million. We reduced it to $175 million, based on getting to the end of the year and having more information now that it's March.

    我快速補充幾點:你問到現金重組(cash restructuring)。這是我們目前的估計。我們先前估計為 2 億美元。隨著接近年底、且現在已到 3 月掌握更多資訊,我們把它下修到 1.75 億美元。

  • As you might remember from a prior call, or more than a prior call, the Salix severance is a big piece of that. There's a lot of Salix charges that were paid out for over year. So that is still flowing through just based on how the severance was structured.

    你可能記得在先前的電話會議——不只一次——提過,Salix 的資遣費是其中很大的一部分。有許多 Salix 的費用是在一年期間陸續支付。因此,這部分仍在持續反映,主要取決於資遣方案的設計方式。

  • On contingent consideration milestones and payments, again, that number does include the Sprout payment, which is done. The other big payment is there is the $150 million milestone payment for the drug that's listed on the page. What I would say is depending, there's some things that's scheduled for fourth quarter, and if they don't happen in fourth quarter, they could happen in first quarter but that's our best estimate.

    至於或有對價(contingent consideration)的里程碑與付款,同樣地,該數字包含已完成的 Sprout 付款。另一筆較大的付款是頁面上所列藥品的 1.5 億美元里程碑付款。我要說的是,視情況而定,有些事項原本排在第四季;若第四季未發生,可能會在第一季發生,但這是我們目前最好的估計。

  • - Company Group Chairman

    - Company Group Chairman

  • So I'll add -- this is Anne.

    我再補充——我是 Anne。

  • I'll add a few comments just on managed care, to add to what Mike had said. So I do want to emphasize, as Mike said, the payer negotiations are going very well. The process is you usually get your Part D bids in the first quarter of the year, and then you have the negotiation process until the plans have to submit into CMS and you're usually notified in the third quarter of the decision.

    我就管理式醫療再補充幾點,延續 Mike 剛才的說法。我確實要強調,如同 Mike 所說,付款方談判進展非常順利。流程通常是:你會在第一季提交 Part D 的投標(bids),接著進入談判流程,直到各計畫必須提交給 CMS;通常你會在第三季收到決定通知。

  • So we feel good about our submissions. We've been going back and forth with the payers. The commercial contracts are on different schedule based on the terms of our contract, and I mentioned the ad hocs, or therapeutic reviews.

    因此我們對提交內容感到樂觀。我們一直與付款方來回溝通。商業合約(commercial contracts)則依合約條款而有不同時程;我也提到過臨時性的(ad hoc)或治療性審查(therapeutic reviews)。

  • With regard to your question around portfolio and how our portfolio helps us, well, number one, Valeant has a sizable portfolio now in the US with over $8 billion in sales. So we are important payers, as they are important to us. We evaluate with each payer how we build our contract with them based on their needs and how they go about it.

    關於你問到的產品組合,以及我們的產品組合如何幫助我們:第一,Valeant 目前在美國擁有相當龐大的產品組合,銷售額超過 80 億美元。因此我們對付款方很重要,正如付款方對我們也很重要。我們會針對每一個付款方,依其需求與其運作方式,評估如何與其建立合約架構。

  • Where it makes sense, we are leveraging our portfolios like in ophthalmology or dermatology and GI and various formats. So, I think that covers your questions on the payers.

    在合理且有意義的地方,我們會運用我們的產品組合,例如在眼科、皮膚科、腸胃科(GI)以及各種形式的組合。所以,我想這回答了你關於付款方的問題。

  • - Analyst

    - Analyst

  • Thank you.

    謝謝。

  • - CEO

    - CEO

  • Next question, please.

    請下一題。

  • Operator

    Operator

  • Tim Chang, BTIG.

    Tim Chang,BTIG。

  • - Analyst

    - Analyst

  • Hi, Mike.

    嗨,Mike。

  • Could you talk a little bit more about the non-core assets that you would consider selling? I mean, certainly, you've got a lot of debt on your books. You're trying to revamp the business and I realize you've just gotten back, but it just seems like given how the stocks reacting in the pre-market and all the investors' concerns, wouldn't that repayment be one of your largest priorities right now?

    你能否再多談一點你們會考慮出售的非核心資產?我的意思是,當然,你們的資產負債表上有很多債務。你們正試圖重整業務,我也理解你才剛回來,但看起來,考量到盤前股價的反應以及投資人的各種疑慮,償還債務難道不應該是你們目前最大的優先事項之一嗎?

  • - CEO

    - CEO

  • It is. Fully agree. We are very committed, as Linda said, in 2016 and -- to reduce our debt. That we have not changed that commitment. We will do that through generating cash flow.

    是的。完全同意。正如Linda所說,我們在2016年非常致力於——降低我們的債務。我們並沒有改變這項承諾。我們將透過產生現金流來做到這一點。

  • We hope to generate more cash this year than what we're projecting at this point, but projections are projections. We'll be looking at revenue enhancement. We will be looking at further cost reduction because what we've done is taken revenue down significantly. We have not attacked the cost space in any major way, and that's something we will do.

    我們希望今年能產生比目前預測更多的現金,但預測終究只是預測。我們會著眼於提升營收。我們也會進一步降低成本,因為我們所做的是大幅下調營收。我們尚未在成本端做任何重大的攻堅,而這是我們將要做的事情。

  • We will continue to look at opportunities to raise cash through divestitures. As I mentioned, I'm not going to get into specifics, but you should expect that there will be a series of non-core divestitures over the course of the year, which we will use that cash to pay down debt, and to accelerate the debt paydown.

    我們也會持續尋找透過資產剝離來籌措現金的機會。如我所提,我不會談具體細節,但你們可以預期今年會有一系列非核心資產的處分,我們將用這些現金來償還債務,並加速去槓桿、加快還債。

  • - Analyst

    - Analyst

  • Mike, is the fact that your tax rate is going up or you're changing your reporting, especially on your tax rate, is that part of -- is that tied to the fact that you're deleveraging the balance sheet at all?

    Mike,你們稅率上升或你們正在改變申報方式,特別是稅率的呈報方式,這是否——是否與你們在資產負債表去槓桿有任何關聯?

  • - CEO

    - CEO

  • No, no. Every year there is a comment letter from the SEC. It is not the investigation. It is a comment letter that all companies get. We sit down with the SEC ; it's a change, as Rob said, that they suggested. We thought their suggestion made a lot of sense. But I think the key, from an invest -- from an equity investor standpoint and also from a debt standpoint, is that it has zero impact on our cash flows, right?

    不,不是。每年SEC都會發出一封意見函(comment letter)。這不是調查。這是一封所有公司都會收到的意見函。我們會與SEC坐下來討論;這是一項變更,正如Rob所說,是他們建議的。我們認為他們的建議很有道理。但我認為關鍵在於,從投資人——從股權投資人的角度以及從債權人的角度來看,它對我們的現金流完全沒有影響,對吧?

  • It's -- so the reported tax rate will change because the NOLs -- it will be pre-NOL in terms of what's reported, but in terms of the actual taxes paid, our previous guidance still stands. We expect it to stay in the 5% range. So it's purely a presentation, a difference that has zero impact at all in terms of generation of cash flows.

    也就是說,報導的稅率會改變,因為NOL(淨營運虧損結轉扣抵)——呈報上會以扣除NOL之前(pre-NOL)的口徑來呈現;但就實際繳納的稅金而言,我們先前的指引仍然有效。我們預期會維持在約5%的區間。所以這純粹是呈列方式的差異,對現金流的產生完全沒有任何影響。

  • - Analyst

    - Analyst

  • Okay.

    好的。

  • - CEO

    - CEO

  • Why don't you get back in queue, just because we have a lot of names on the board here.

    你先回到提問隊列後面吧,因為這裡板上還有很多人排隊。

  • - Analyst

    - Analyst

  • Okay. Will do.

    好的。會的。

  • Operator

    Operator

  • Chris Schott, JPMorgan.

    Chris Schott,摩根大通。

  • - Analyst

    - Analyst

  • Great. Thanks very much. Just two questions here.

    很好。非常感謝。我這裡有兩個問題。

  • First, I know you ran through in a lot of detail, the reasons for the updated guidance, but more broadly, how did so much change so quickly with the business? I think what investors are trying to put their hands around is, how much of this guidance is conservativism, or just difference approach to guidance, given the management disruptions and controversies as compared to a deterioration of fundamentals over the last three months? So any color there would be really helpful.

    第一,我知道你們已非常詳細地說明更新指引的原因,但更宏觀地看,業務怎麼會在這麼短的時間內變化這麼大?我想投資人試圖釐清的是:這份指引有多少是出於保守,或只是因管理層動盪與爭議而採取不同的指引方式;相較之下,過去三個月基本面是否真的惡化?如果能就此提供一些補充說明會很有幫助。

  • The second question is just coming back to the divestitures. I know you're not planning to divest core assets, but as you're just thinking about the evolution of Valeant, once you address some of these near-term challenges, if the stock doesn't recover, what would cause the Company to go down a path and consider a broader break-up of the Valeant business units. Thanks very much.

    第二個問題是回到資產剝離。我知道你們不打算出售核心資產,但當你們在思考Valeant的演進、並在解決一些短期挑戰之後,如果股價仍未回升,什麼情況會促使公司走上一條路徑,去考慮更大範圍地拆分Valeant各個事業單位?非常感謝。

  • - CEO

    - CEO

  • Sure. So in terms of, if you look at what's happening, the -- one of the big differences and the reduction in guidance is Q1. In a sense, we've lost a quarter. So Q1 is -- and that's -- which is why we tried to show Q2 through Q1 of next year where we made very conservative assumptions on Q1 of next year. All we did is took Q1 of this year, what we expected and added it to it.

    當然。就目前發生的情況而言——指引下修的一個主要差異在於第一季(Q1)。某種意義上,我們等於少了一個季度。所以Q1是——也正因如此,我們試圖展示從Q2到明年Q1的情況,並對明年Q1做了非常保守的假設。我們所做的只是把今年Q1原本的預期加回去。

  • So on a going forward basis, and I don't think there's been a big deterioration at all in the business. If you see the script trends, things like FX, you just live with, so that's a piece of it. I think we have the managed care environment was something that we certainly needed to address. So that is -- certainly has led us to, I think, a more conservative outlook on revenues than what we had before. So hopefully, those are numbers that we can meet and beat.

    因此從未來展望來看,我不認為業務有任何重大的惡化。如果你看處方量(script)趨勢、以及像匯率(FX)這類因素,你只能接受並與之共存,這是其中一部分。我認為受管醫療(managed care)環境是我們確實需要處理的事情。因此——這確實使我們對營收的展望比之前更保守。所以希望這些數字是我們能夠達成並超越的。

  • There was a pretty high deductible planned impact in the first quarter. It's at now up to 26% of our lives, so each year that increases, so first quarter will always be tough. So I think it's a first-quarter phenomenon. We feel good about the rest of the year; the fundamentals are good. And probably, we have taken a little bit more conservative approach on forecasting.

    第一季受到高自付額(high deductible)方案的影響相當大。目前這已涵蓋到我們26%的受保人數(lives),而且每年都在增加,所以第一季總是會比較艱難。所以我認為這是第一季的現象。我們對今年其餘時間感覺良好;基本面是好的。而且可能我們在預測上採取了稍微更保守的做法。

  • In terms of if the stock price does not recover, I think that will be a function of not delivering the cash flows that we're promising and/or exceeding the cash flows. And then the Company should think about other moves, as I think, as we're here to serve shareholders. I know the Board is committed to that.

    至於如果股價沒有回升,我認為那將取決於我們是否能交付我們承諾的現金流,和/或是否能超出這些現金流。然後公司就應該思考其他動作,因為我們在這裡是為股東服務。我知道董事會對此是承諾的。

  • I know management is committed to it, but we do think we have a plan that will generate strong cash flows and allow us to reduce debt and we can demonstrate real growth, organic growth in our businesses. I think we believe as we're successful doing that. The stock price will start trading more on fundamentals, which is not right now.

    我知道管理層也承諾如此,但我們確實認為我們有一個計畫,能產生強勁的現金流、讓我們降低債務,並且能在各項業務中展現真正的成長、內生成長。我想我們相信,只要我們成功做到這些。股價就會開始更多地依基本面交易,而目前還不是。

  • Thanks for the questions, Chris. We'll move on.

    謝謝你的提問,Chris。我們繼續下一位。

  • Operator

    Operator

  • Corey Davis, Canaccord Genuity.

    Corey Davis,Canaccord Genuity。

  • - Analyst

    - Analyst

  • Thanks very much.

    非常感謝。

  • Just probably two questions. Number one, would you be willing to give Xifaxan-normalized run rate ex-inventory on an annualized basis to $10 million in Q4. But I suspect that once inventories are normalized, starting in Q2 of this year, it's going to be much higher than that.

    大概兩個問題。第一,你是否願意提供在剔除庫存因素後、以Xifaxan常態化(normalized)的年化運行率(run rate)?第四季(Q4)是1,000萬美元,但我猜一旦庫存正常化,從今年第二季(Q2)開始,這個數字會高得多。

  • - CEO

    - CEO

  • And the second question?

    第二個問題呢?

  • - Analyst

    - Analyst

  • The second question is how do you think your retention program is going now and will be going over the next six months to ensure that you keep, retain and empower all your key employees, not just at the upper levels, but all the way down the ranks?

    第二個問題是,你認為你們的留任計畫目前進展如何?以及在接下來六個月將如何推進,以確保你們能留住、保留並賦能所有關鍵員工,不僅是高層,還包括各個層級的員工?

  • - CEO

    - CEO

  • So let me tell you about retention and that I'll have Ari talk a little bit about Xifaxan. So far, the retention program is working. We've had very few losses. We've obviously lost Deb Jorn and that -- we're disappointed. It was interesting. On the EMT, at the very senior level, we don't have a retention program, right?

    那我先跟各位談談留任,接著我會請 Ari 稍微談一下 Xifaxan。到目前為止,留任計畫運作良好。我們的流失非常少。我們顯然失去了 Deb Jorn,對此——我們很失望。這很有意思。在 EMT(高階管理團隊)層級、也就是非常資深的層級,我們其實沒有留任計畫,對吧?

  • We did not put that in place for -- we had nothing in place currently for the EMT. Well, she was a member. What we have is below the EMT, we have about 70 people that are in, what we call, AIP, which are sort of our next level key. We've had minimal, if any, losses there. We just paid bonuses for the year on Friday. So this is -- we'll see what happens in the next few weeks.

    我們沒有為——我們目前對 EMT 並沒有任何留任安排。嗯,她是其中一員。我們有的是在 EMT 之下,我們大約有 70 人納入我們所稱的 AIP,可視為下一層的關鍵人才。那裡的流失幾乎沒有,即便有也非常少。我們剛在週五發放了年度獎金。所以這——接下來幾週我們會看看情況如何。

  • There is a sort of a camaraderie. We have a meeting with the AIP group every week, where we have an open discussion and with the leaders of the Company and there's a very positive attitude in the group that were committed.

    團隊之間有一種同袍情誼。我們每週都會與 AIP 團體開會,進行開放式討論,並與公司領導層交流;而且這個團體有非常正向的態度,大家都很投入、很承諾。

  • I think they know how strong our brands are, how strong our products are. They have spent a lot of time with our customers, be it physicians, be it retailers, and many of them have been at other pharma companies and have gotten through similar types of experiences. So I think there is an esprit d'corps. We're hopeful the Board was very supportive of what we believe is to be a pretty generous retention program for this level. So, so far so good. But as you probably point out, it's tough. Right now, it's a bit of a tough Company to work for. So I really thank our employees for their commitment and dedication.

    我想他們知道我們的品牌有多強、我們的產品有多強。他們花了很多時間與客戶互動,不論是醫師或零售商;而且其中許多人曾在其他製藥公司任職,也經歷過類似的情況。所以我認為確實有一種團隊精神。我們也很樂觀,董事會非常支持我們所認為在這個層級相當慷慨的留任計畫。所以,到目前為止一切都還不錯。但如你可能指出的,這很艱難。就目前而言,這家公司確實有點難待。所以我非常感謝員工的承諾與投入。

  • Ari, on Xifaxan?

    Ari,談談 Xifaxan?

  • - Company Group Chairman

    - Company Group Chairman

  • On Xifaxan, I believe we said, back in December, we expect it will be greater than a $1 billion drug this year. We obviously expect that to be the case. We have over 400 reps in the field promoting Xifaxan, and we continue to believe that we will see growth across both IBSD, and increasingly HE, where as we've said before, the medical indications for permanent use of Xifaxan with lactulose is in the guidelines and we're just put -- we're putting in another 100 reps into the field.

    關於 Xifaxan,我相信我們在去年 12 月說過,我們預期今年它會成為一款年銷售額超過 10 億美元的藥物。我們顯然仍預期會如此。我們在第一線有超過 400 位業務代表推廣 Xifaxan,我們也持續相信在 IBSD 以及日益重要的 HE 兩個領域都會看到成長;正如我們先前所說,Xifaxan 與 lactulose 併用作為長期使用的醫療適應症已被納入治療指引,而我們——我們正再增派 100 位業務代表到第一線。

  • They have just gone through training. So we're putting a lot of energy behind the drug. Scripts are, as Mike said, you see them, they're running north of 12,000 a week. In total this year, we expect to see in and around 50% growth in total Xifaxan scripts.

    他們剛完成訓練。所以我們在這個藥物上投入了大量精力。處方量方面,如 Mike 所說,你們也看得到,目前每週超過 12,000 張。今年整體而言,我們預期 Xifaxan 的總處方量將成長約 50% 左右。

  • - CEO

    - CEO

  • Thank you, Corey. Next question.

    謝謝你,Corey。下一個問題。

  • - Analyst

    - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Shibani Malhotra, Nomura Securities.

    Nomura Securities 的 Shibani Malhotra。

  • - Analyst

    - Analyst

  • Thanks for the questions. I've got a couple.

    謝謝讓我提問。我有幾個問題。

  • The first is, Mike, can you just clarify, you were saying that the reason the Salix inventory or Salix revenues are being brought down is because managed care didn't read the Walgreens press release correctly? Is that correct? It's a bit -- that's a bit difficult to fathom that it would have such a big impact on your sales.

    第一個問題是,Mike,你能否釐清一下:你剛才是說,Salix 的庫存或 Salix 的營收之所以被下修,是因為受管制醫療(managed care)沒有正確解讀 Walgreens 的新聞稿?是這樣嗎?這——這有點難以理解,竟然會對你們的銷售造成這麼大的影響。

  • And then second, over the last six months, we've been talking to you and investors have as well about the fact that management needs to rebuild credibility with investors. And we've been through a spate of negative news that started with pricing and then Philidor, then just general communication and now the guidance, which I would say is lowered far more than any investor anticipated.

    第二個問題是,過去六個月,我們一直在跟你們溝通,投資人也同樣在談:管理層需要重建在投資人心中的可信度。而我們經歷了一連串負面消息,先是定價,接著是 Philidor,然後是整體溝通問題,現在又是財測指引——我會說這次下修幅度遠超過任何投資人的預期。

  • The question is, how can we be confident in what you're saying today about the business, given that you were positive in December and January? How do we get comfortable that Valeant is able to execute and deliver for shareholders?

    問題是:鑑於你們在 12 月與 1 月時仍偏正面,我們要如何對你們今天對業務的說法有信心?我們要如何放心 Valeant 能夠執行並為股東交付成果?

  • Thanks.

    謝謝。

  • - CEO

    - CEO

  • Maybe I misspoke. In terms of the first one, it's not managed care per se, because managed care doesn't actually order any product. Distributors and retailers order the product, which lead to revenue recognition. So and -- again, I think Walgreens did not do a very good job explaining and then there were aspects of the Walgreens program that people didn't like.

    也許我剛才說得不夠精確。就第一點而言,並不是受管制醫療本身,因為受管制醫療其實不會直接下單任何產品。是經銷商與零售商下單,進而觸發營收認列。所以——再說一次,我認為 Walgreens 在說明上做得不是很好,而且 Walgreens 計畫中有一些部分讓人不喜歡。

  • So I think we've done a better job explaining. We've modified the program to accommodate important channel partners. I don't think it would be -- and then there was some lack of clarity of whether GI was part of the program or not. So on that one, I wouldn't necessarily agree that it was completely unexpected, the negative response to the GI. But I would point to the script. In end, demand is based on scripts written and filled.

    所以我認為我們已經做了更好的說明。我們也修改了該計畫,以配合重要的通路夥伴。我不認為那會——另外,當時也不夠清楚 GI(腸胃科)是否屬於該計畫的一部分。所以就這點而言,我不一定同意對 GI 的負面反應是完全出乎意料。但我會回到處方量。歸根結底,需求是由開立並實際配藥的處方所驅動。

  • I point to the continued strong script growth across the sales portfolio, as being the leading indicator of how that's doing and we're quite pleased with the growth that we continue to see. As Ari said, we are putting more resources behind it, because we think there's a lot of untapped growth in Xifaxan, in particular, in the HE indication.

    我會指出,整個銷售產品組合的處方量仍持續強勁成長,這是衡量進展的領先指標;而我們對於持續看到的成長相當滿意。如 Ari 所說,我們正投入更多資源,因為我們認為 Xifaxan 仍有大量尚未開發的成長空間,特別是在 HE 適應症上。

  • In terms of management credibility, we have to earn it. You raised some terrific points. I would argue January, I don't think we said -- I don't think I said a whole lot in January. I think I was in the hospital then, but I do accept your point and it starts with me. So our teams have been working hard and we obviously have to deliver on our commitments.

    至於管理層的可信度,我們必須靠表現去贏回來。你提出了一些非常好的觀點。我會說 1 月——我不認為我們說了——我不認為我在 1 月說了很多。我想我那時在住院,但我接受你的觀點,而且這要從我開始。所以我們的團隊一直很努力,而我們顯然必須兌現我們的承諾。

  • The world has changed to some degree since December, but we have to do a better job. We've got some underperforming businesses; that's on us, right? That's totally on us. So we have to earn back the credibility. We have to deliver on our results. We have to meet or exceed this guidance, and I think we all recognize that.

    自 12 月以來,外部環境在某種程度上已經改變,但我們必須做得更好。我們有一些表現不佳的事業;那是我們的責任,對吧?那完全是我們的責任。所以我們必須重新贏回可信度。我們必須交出成果。我們必須達成或超越這份指引,我想我們都明白這點。

  • So it's a bit of a starting over point at this point for me and the Company. Clearly, if we don't deliver, then again, I'll -- that's on me. But I can assure you I'm completely committed to making sure that we do deliver and I do think we have a lot more line of sight in terms of managed care at this point. We have a lot more line of sight in terms of pricing at this point.

    所以對我和公司而言,這有點像是此刻重新開始的一個起點。很明顯,如果我們做不到——那同樣地,我會——那是我的責任。但我可以向你保證,我完全致力於確保我們能交付成果;而且我確實認為,就受管制醫療而言,我們目前的能見度高了很多。就定價而言,我們目前的能見度也高了很多。

  • I think we have a better line of sight in terms of script practice. So I think that -- all three of those helps. There are certain things we don't control, like FX. But we have built our guidance so we hope that's manageable as well. But thank you for the questions, Shibani. And we'll go to the next one.

    我認為在處方行為方面,我們的能見度也更好了。所以我認為——這三點都有幫助。有些事情我們無法控制,例如匯率(FX)。但我們在編製指引時已將其納入考量,因此我們希望那也是可控、可管理的。不過謝謝你的提問,Shibani。我們進入下一題。

  • Operator

    Operator

  • Umer Raffat, Evercore ISI.

    Umer Raffat,Evercore ISI。

  • - Analyst

    - Analyst

  • Thanks for taking my question. I have a few today, if I may. I just really want to focus in on the -- some of the changes and fundamental business that seems to be coming out in first quarter. So first few for Mike, if I may. Mike, how different is the guidance number today versus what you came out -- versus when you first came back a couple weeks ago?

    感謝讓我提問。如果可以的話,我今天有幾個問題。我主要想聚焦在第一季看起來浮現的一些變化與基本面業務。所以先問 Mike 幾個問題,如果可以的話。Mike,今天的指引數字和你幾週前剛回來時提出的——也就是你最初回來時——相比,有多大不同?

  • And then on the Xifaxan, what I'm trying to understand is, if orders were cancelled towards the end of first quarter but the TRX continues to grow, that would imply to me that there's more inventory in the channel than expectation. Am I on the right track there?

    另外關於 Xifaxan,我想釐清的是:如果第一季末出現訂單取消,但 TRX 仍持續成長,這對我而言意味著通路庫存比預期更多。我這樣理解對嗎?

  • And then on Ophthalmology RX, I don't see any disruption on IMS, so I'm trying to understand, what is it that you're seeing disruption-wise. And the first quarter base business trends, too, Mike, how does the January plus February compare to what you're seeing in March?

    再來關於眼科處方(Ophthalmology RX),我在 IMS 上看不出任何中斷,所以我想了解你們看到的中斷究竟是什麼。另外第一季基礎業務趨勢也是,Mike,1 月加 2 月相較於你們在 3 月看到的情況如何?

  • And then Rob, I'm sorry, if I may, a couple things. Number one, free cash. On EBITDA to free cash flow bridge, you previously mentioned working capital change of $600 million; it's now $200 million, so what's driving that? Is it just Walgreens?

    然後 Rob,不好意思,如果可以的話也問幾點。第一,自由現金。在 EBITDA 到自由現金流的橋接中,你們先前提到營運資金變動為 6 億美元;現在變成 2 億美元,是什麼在驅動?只是因為 Walgreens 嗎?

  • Secondly, Rob, tax rates, Howard previously said, if you do delever cash taxes going to the low teens versus about the mid-single digits that it used to be. So my question is if you do delever, would the non-GAAP tax rate approach 20%? And then finally on EBITDA for 2017 -- for the next four quarters, so the press release says that adjusted EBITDA for the next four quarters will be $6.2 billion to $6.6 billion but the Slide 16, I believe, says it's $6 billion. So I just want understand that. Thank you.

    第二,Rob,稅率方面,Howard 先前說過,如果去槓桿,現金稅會到低十幾個百分點,而不是以前的中個位數。所以我的問題是:如果你們去槓桿,non-GAAP 稅率會接近 20% 嗎?最後,關於 2017 年 EBITDA——也就是未來四個季度,新聞稿說未來四個季度的調整後 EBITDA 為 62 億到 66 億美元,但我記得第 16 頁投影片寫的是 60 億美元。所以我想了解這點。謝謝。

  • - CEO

    - CEO

  • That's a lot of questions, Umer. Let's try to pick them off. I'll start. So guidance design that we have had -- been having a lot of debate within management and with the Board, in terms of where we take guidance and quite frankly, we've had -- continue to have discussions. We've made a lot of progress with managed care over the last couple of weeks.

    問題很多,Umer。我們盡量逐一回答。我先開始。關於我們的指引設計——管理層內部以及與董事會之間一直有很多討論,關於指引要落在哪裡;坦白說,我們也一直——仍在持續討論。過去幾週我們在受管理醫療(managed care)方面取得了很大進展。

  • So again, we have -- some of the numbers -- some of the negatives have increased. But there's certainty around them. And then the first quarter, we've gotten a lot more clarification on first quarter as the quarter has progressed. We feel comfortable with the guidance that were -- we gave out this morning.

    所以再說一次,我們有——一些數字——一些負面因素變得更大。但對這些因素的確定性更高。另外第一季方面,隨著季度推進,我們對第一季的情況也獲得更多釐清。我們對今天早上給出的指引感到有把握。

  • In terms of inventory, as you said, if scripts continue to grow, but people aren't ordering as much product, it's one of two things. One is there is more inventory out there than we thought. The second is, people are holding lower levels of inventory, right? Those are the two possible explanations.

    就庫存而言,如你所說,如果處方量持續成長,但大家訂貨量沒那麼多,可能有兩種情況。第一是通路上的庫存比我們想的更多。第二是大家把庫存水位壓得更低,對吧?這就是兩種可能的解釋。

  • And actually, we think it's a little bit of the latter in terms of both distributors and retailers. They also focused on cash management and we do think inventories throughout the channel continue to go down. But by definition, it's scripts continuing to grow. At some point we do believe as we get into the second quarter, everything will be normalized.

    而實際上,我們認為比較偏向後者,無論是經銷商或零售端都是如此。他們也更重視現金管理,我們確實認為整個通路的庫存仍在下降。但按定義來說,處方量仍在持續成長。我們相信進入第二季後,在某個時間點一切都會回到正常。

  • Ophthalmology, again, I don't think we said there's a major change. There is not a major change. What we have is a set of older products that, alone, are -- where we're experience a slow decline. This is not -- actually, our branded share is increasing; this is largely due to more and more generics is what's growing, and the pool of branded ophthalmology products in the areas we compete is going down.

    眼科方面,再次說明,我不認為我們說過有重大變化。確實沒有重大變化。我們有一組較老的產品,單就這些產品而言——我們正經歷緩慢下滑。這不是——其實我們的品牌市占在提升;主要原因是越來越多學名藥在成長,而我們所競爭領域中的品牌眼科產品池正在縮小。

  • Now we have not included in our guidance any new launches. If we get approval on our glaucoma drug, then we would expect that, that would be help bolster ophthalmology. Similarly, in dermatology, if we approval on some of our pipeline products, that we'll enhance there, so what we're forecasting now in our guidance is products that are currently on the market.

    另外,我們在指引中沒有納入任何新上市產品。如果我們的青光眼藥物獲得核准,我們預期那將有助於支撐眼科業務。同樣地,在皮膚科方面,如果我們的一些研發管線產品獲得核准,也會帶來提升;因此我們目前在指引中所預測的是現有已上市產品的表現。

  • We don't have launched products in there. In terms of progression, January, February, March, March was always the much larger month than January or February. It's even more in the first quarter. Because of these high deductible plans, it's even more acute in terms of what we see in March, but -- so clearly, March is a much better month than January and February.

    我們沒有把新上市產品納入其中。就月度走勢而言,1 月、2 月、3 月,3 月一向比 1 月或 2 月大得多。在第一季更是如此。由於這些高自付額(high deductible)計畫,我們在 3 月看到的情況更為明顯;但——很清楚,3 月是比 1 月和 2 月好得多的一個月。

  • Rob, there are number of --

    Rob,有幾個——

  • - CFO

    - CFO

  • So let me take yours in turn. Firstly, with respect to the working capital on Slide 20, the reduction reflects the lower growth in the updated guidance, and it's simply 30% of the change in revenue. In terms of the tax rate, I agree that, over time, it would increase if we were to delever the 10% to 15% that we are showing is to try to do it on a comparable basis to the 5% that we were showing.

    我依序回答你的問題。第一,關於第 20 頁投影片的營運資金,這個下降反映了更新後指引中的較低成長,基本上就是營收變動的 30%。至於稅率,我同意,隨著時間推移,如果我們去槓桿,稅率會上升;我們所呈現的 10% 到 15% 是為了與先前呈現的 5% 做可比基礎。

  • I think we've always said that our -- over the longer term, our tax rate would increase and likewise and commensurate the 10% to 15% would increase. And with respect to the fourth-quarter guidance, which Mike presented on Page 16. The chart is correct. The adjusted EBITDA non-GAAP guidance is $6 billion and we will correct that.

    我想我們一直都說,從較長期來看,我們的——稅率會上升;同樣地,相應地,10% 到 15% 也會上升。至於第四季指引,也就是 Mike 在第 16 頁所呈現的。圖表是正確的。調整後 EBITDA 的 non-GAAP 指引是 60 億美元,我們會更正那個(不一致之處)。

  • - Analyst

    - Analyst

  • Wait, Rob, to be clear, the next four quarters' EBITDA is $6 billion?

    等等,Rob,確認一下,未來四個季度的 EBITDA 是 60 億美元?

  • - CFO

    - CFO

  • Correct.

    正確。

  • - Analyst

    - Analyst

  • Or $6.2 billion to $6.6 billion?

    還是 62 億到 66 億美元?

  • - CFO

    - CFO

  • $6 billion.

    60 億美元。

  • - CEO

    - CEO

  • Next question, please.

    下一題,請。

  • Operator

    Operator

  • David Risinger, Morgan Stanley.

    David Risinger,Morgan Stanley。

  • - Analyst

    - Analyst

  • Thanks very much. I have 13 questions also. (laughter) but I'll keep it a little bit briefer.

    非常感謝。我也有 13 個問題。(笑聲)但我會簡短一點。

  • So first, with respect to divestitures, should we expect them to be dilutive to EPS, given the fact that you'll be paying off low interest rate debt? Second, with respect to the rebates, discounts and channel fees, including Walgreens, could you just explain to us -- I'm assuming most of those are netted out of revenue and are reflected in net revenue. But any of those channel payments, et cetera, reflected in COGS, or SG&A? And then finally, with respect to launches, Mike, you mentioned that you're excluding launches from revenue guidance, are you also excluding launch expenses from your guidance, as well?

    首先,關於資產剝離(divestitures),考量到你們將償還低利率債務,我們是否應預期這會對 EPS 造成稀釋?第二,關於回扣、折扣與通路費用(包含 Walgreens),你們能否向我們說明——我假設其中大多數會自營收中扣除並反映在淨營收。但這些通路付款等項目,有任何是反映在銷貨成本(COGS)或銷售、一般及管理費用(SG&A)中嗎?最後,關於新上市產品(launches),Mike,你提到你們在營收指引中排除了新上市產品,那你們是否也在指引中排除了上市費用(launch expenses)?

  • Thank you.

    謝謝。

  • - CEO

    - CEO

  • Thank you, David, for prioritizing your questions. I hope your colleagues take from your lead. So thank you very much.

    謝謝你,David,優先安排你的問題。我希望你的同事能以你為榜樣。所以非常感謝。

  • Depending on the divestitures, some could be dilutive, some actually may not be. It kind of depends on the assets. If it's an early stage asset, if it's on -- obviously, it's not -- so as you know, it really depends on the asset and the price we get.

    視資產剝離而定,有些可能會造成稀釋,有些其實可能不會。這有點取決於資產本身。如果是早期階段的資產,如果它在——顯然,它不是——所以如你所知,這真的取決於資產以及我們能拿到的價格。

  • If we do anything major, it could be -- it could lower our EPS. There is no question about that. But we'll be clear, just like we are -- if, when in the past, when we made acquisitions, whether it will be or won't be dilutive. In terms of the launch expenses are also not included in the budget. But I will note that launches, in the area of dermatology and ophthalmology, we don't anticipate major changes to our infrastructure.

    如果我們做任何重大的動作,可能會——可能會降低我們的每股盈餘(EPS)。這點毫無疑問。但我們會說清楚,就像我們——如果、在過去我們進行收購時一樣,會說明它是否會造成稀釋。至於上市(launch)費用,也沒有納入預算。但我要指出的是,在皮膚科與眼科領域的產品上市,我們不預期需要對我們的基礎設施做重大變動。

  • I think it will -- we would prioritize our call patterns differently. But the launch, we do have good strong critical mass in dermatology and ophthalmology and in GI in terms of our sales force capabilities, et cetera. I don't anticipate we will adding lots of people for -- as part of these launches.

    我認為這將——我們會以不同方式來優先安排拜訪(call)模式。但就上市而言,我們在皮膚科、眼科以及腸胃科(GI)方面,就銷售團隊能力等而言,已具備相當強的規模與臨界量。我不預期我們會因為這些上市而增加很多人員。

  • In terms of Walgreens, in terms of revenue reductions versus COGS, I think we're taking the Walgreens costs through our SG&A, in terms of how that's how we're retrieving the Walgreens. They are doing -- we're basically paying them a dispensing fee based on activity. And that will run through, so it will not be in that reduction of revenue, it will be in the -- it will flow through SG&A.

    關於 Walgreens,就營收減少相對於銷貨成本(COGS)而言,我認為我們是把 Walgreens 的成本列在銷售、一般及行政費用(SG&A)中,這就是我們處理 Walgreens 的方式。他們在做——我們基本上是依活動量支付他們一筆調劑(dispensing)費用。而這會走那個科目,所以不會反映在營收減少那一項,而是會在——會流入 SG&A。

  • Thank you for your questions, David. Next question, please.

    謝謝你的提問,David。請下一題。

  • Operator

    Operator

  • David Amsellem, Piper Jaffray.

    David Amsellem,Piper Jaffray。

  • - Analyst

    - Analyst

  • Thanks. I just have two.

    謝謝。我只有兩個問題。

  • So first, I -- on the tax reporting, the new tax reporting. And I know you made it clear that there's no impact on cash flow or actual taxes paid. But what I'm trying to understand here is under the old reporting, you had characterized your EPS guidance ranges and you reported EPS as cash EPS, so under the old reporting for past EPS, is that cash EPS not really, quote, cash EPS? I'm just trying to understand if there's an inconsistency here.

    首先,我——關於稅務申報、新的稅務申報。我知道你已經說得很清楚,對現金流或實際繳納的稅金沒有影響。但我想理解的是,在舊的申報方式下,你把 EPS 指引區間描述為、並且你報告的 EPS 是現金 EPS(cash EPS),所以在舊的申報方式下,過去的 EPS,那個現金 EPS 其實並不是真正意義上的、所謂的現金 EPS 嗎?我只是想了解這裡是否存在不一致。

  • And then secondly, this is a high-level question. Can you -- I think one of my peers had talked -- asked about retention earlier. Maybe, can you speak to morale in the Company and you talked about distractions. Can you speak to that and how that potentially would impact the business, and is there an issue internally, in your view, in terms of confidence in your ability to lead the Company going forward, given what's transpired?

    第二,這是一個高層次的問題。你能不能——我想我有位同業先前談到——問過留任(retention)的問題。也許你能談談公司士氣,你也提到分心的因素。你能談談這點,以及它可能如何影響業務?另外,就你看來,內部是否存在問題:就你未來領導公司前進的能力而言,鑑於已發生的事情,內部對此的信心是否受到影響?

  • Thank you.

    謝謝。

  • - CEO

    - CEO

  • All right. So I'm going to ask -- let's take your second question first and then Rob, we can talk about the tax.

    好的。所以我會先——我們先回答你的第二個問題,然後 Rob,我們再談稅務。

  • I'm going to ask Ari and Anne, because I've already commented a little bit on morale. I'd like to get their takes. And the large portions of the Company report to both of them in terms of the people side. So I will address the personnel question, but Ari and Anne, why don't you -- Ari you can go first and talk about what you think about morale?

    我會請 Ari 和 Anne 來回答,因為我之前已經對士氣稍作評論。我想聽聽他們的看法。而且就人員面而言,公司很大一部分都向他們兩位匯報。所以我會回應人事的問題,但 Ari 和 Anne,你們不如——Ari 你先談談你對士氣的看法?

  • - Company Group Chairman

    - Company Group Chairman

  • Look, I think, Mike, as you said, these are challenging times as we truly have an amazing bench of general managers and leaders of functions in the businesses and you've heard that names repeated again and again. I think we have strong and talented leadership and people who are committed to GI to derm to ophthalmology, Solta, Obagi, Latin America, the BNL businesses and thinking across the teams and these incredibly talented people.

    你看,我認為,Mike,正如你所說,這些是充滿挑戰的時期;但我們確實擁有非常出色的一批總經理與各業務職能的領導者,你也一再聽到那些名字被反覆提起。我認為我們有強大且有才華的領導團隊,以及一群致力於腸胃科(GI)、皮膚科(derm)、眼科、Solta、Obagi、拉丁美洲、BNL 業務的人,並且能跨團隊思考,這些人都非常有才華。

  • We come to work every day, obviously, we have to return money to shareholders, but we come to work worrying about patients, putting quality products into the market, and serving our doctor customers compliantly and to the best of our ability. I think that's what motivates our team. I think we believe in our mission. We believe in what our Company is trying to achieve. That's what we do day to day.

    我們每天來上班,當然,我們必須為股東創造回報,但我們來上班時關心的是病患,把高品質的產品投放市場,並以合規的方式、盡我們所能服務我們的醫師客戶。我認為這就是驅動我們團隊的動力。我認為我們相信我們的使命。我們相信公司想要達成的目標。這就是我們每天在做的事。

  • The issues surrounding us are distracting and it takes courage to forge ahead to execute our mission day-to-day in the face of all that. So all I can say is we have fabulous people. We're blessed to have them. We believe in them and we think they will do the right thing for the Business.

    圍繞著我們的這些議題確實會分散注意力,而在面對這一切的情況下,仍要有勇氣持續推進、每天執行我們的使命。所以我能說的是,我們有非常優秀的人才。我們很幸運擁有他們。我們相信他們,也認為他們會為公司做正確的事。

  • - Company Group Chairman

    - Company Group Chairman

  • So I will just add a few comments to what Ari has said. I think he described it well. When you talk about morale, I think people have worked through the process internally, through a typical change process and people now are actually -- they're angry, I think more about at the outside. They see the Company being described in a way that they know is not what they experience at Valeant.

    所以我再補充幾點 Ari 所說的。我認為他描述得很好。談到士氣,我認為大家在內部已經走過一個典型的變革過程,而現在人們其實——我覺得更多是對外部感到憤怒。他們看到外界以某種方式描述公司,而他們知道那並不是他們在 Valeant 的實際體驗。

  • So I am encouraged that I've really seen people trying to move to action. They want to help. They want to help change the image of the Company and we have really strong leaders who, I think, are channeling that energy into the best thing that everyone can do in this organization to really change and shift the organization is performed every day.

    所以我感到鼓舞的是,我確實看到大家正努力轉向行動。他們想要幫忙。他們想要幫助改變公司的形象,而我們也有非常強的領導者,我認為他們正在把這股能量導向:在這個組織裡,每個人能做的最好的事情,就是每天把工作做好,真正去改變並推動組織轉變。

  • And that's what we are emphasizing each and every day is that really delivering performance is going to get us out of the situation that we're in. I think the tenant that Valeant has really built the organization around a decentralized approach helps us here. Because we have some new businesses who have an identity with a select set of customers who are really building their image even in their onboarding as a Valeant company. One of those being Dendreon, that I think is doing very well.

    而我們每天都在強調的是,真正交出績效將使我們走出目前的處境。我認為 Valeant 以分權式(decentralized)的方式建立組織,對我們在這裡很有幫助。因為我們有一些新業務,對特定客戶群有其自身的身分認同,即使在作為 Valeant 公司的一部分進行整合(onboarding)時,也仍在建立他們的形象。其中之一是 Dendreon,我認為它表現得非常好。

  • And then just a couple of other points. I think we have one of the best incentive comp programs in the industry for our sales representatives, and so that keeps them motivated on clear goals that they can achieve and we're working to shape the environment such that they can do that.

    另外再提幾點。我認為我們對銷售代表的獎酬(incentive comp)方案是業界最好的之一,因此能讓他們在清晰且可達成的目標上保持動力,而我們也正努力塑造環境,讓他們能做到這一點。

  • And I will just end with, I think, Ari's point around people really believing in the products that they're selling. When I talked to our sales reps, when I talk to our marketers, R&D folks, they are very committed that these products that we brought to market and are bringing to market make a real difference in patients' lives.

    最後我想回到 Ari 的觀點:大家真的相信他們所銷售的產品。當我和我們的銷售代表、行銷人員、研發(R&D)同仁交談時,他們都非常投入,因為我們已經推向市場、以及正在推向市場的這些產品,確實能為病患的生活帶來真正的改變。

  • So I think keeping that commitment, that conviction and that determination to really change our image and perform our way out of this, and will keep our organization and the morale going in the right direction.

    所以我認為,維持那份承諾、信念與決心,真正去改變我們的形象,並以績效走出目前的困境,將會讓我們的組織與士氣持續朝正確方向前進。

  • - Company Group Chairman

    - Company Group Chairman

  • Anne, that's a good point. If I could just add to this.

    Anne,這點說得很好。如果我可以再補充一下。

  • There's important functions that enable our front line people to do their work and that specifically manufacturing and R&D and I think [T]age and his team in R&D are cranking our products that are going to fill our pipeline. We talk about put down on a map, IDP-118, and these things are being worked on by this terrific team while remaining focused on the future. I think Dennis, Angelo, and their team in manufacturing as we travel around to the operations, you couldn't hope to bring a team of people more focused on just driving quality and efficiency day to day.

    有一些重要的職能,能讓我們第一線同仁做好他們的工作,特別是在製造與研發方面;我認為[T]age和他在研發的團隊正在全力推進我們的產品,這些產品將會充實我們的產品管線。我們談到把它們標在地圖上,例如IDP-118,而這些事項正由這支出色的團隊在保持聚焦未來的同時持續推進。我認為Dennis、Angelo以及他們在製造端的團隊,當我們走訪各個營運據點時,你不可能期待找到一支比他們更專注於日復一日推動品質與效率的團隊。

  • - CEO

    - CEO

  • David, you're being polite. The question is, am I the appropriate person to lead this Company. It's clearly up to the Board. I do think we have a great Board. We've made a number of new additions to our Board that will provide even more independence.

    David,你太客氣了。問題是,我是否是領導這家公司的合適人選。這顯然取決於董事會。我確實認為我們有一個很棒的董事會。我們已經新增了多位董事會成員,將帶來更高的獨立性。

  • We basically have representation from two activists investors, Pershing Square and ValueAct. I think we have two major investors also on our Board. Our Board interacts with investors, and so I can't comment on, or I'm not going to choose to comment in terms of -- that is up to the Board. But I do think our Board is a lot closer to the investors than many Boards, both given the composition of the new independent directors, as well as representation from a couple of activists. Tax?

    我們基本上有兩位行動派投資人(Pershing Square與ValueAct)的代表。我認為我們董事會中也有兩位主要投資人。董事會會與投資人互動,因此我無法評論,或者我選擇不就——這件事發表評論,因為那取決於董事會。但我確實認為,相較於許多董事會,我們的董事會與投資人更為貼近,這既來自新任獨立董事的組成,也來自幾位行動派的代表。稅務?

  • - CFO

    - CFO

  • Importantly, our tax presentation on Table 2a and 2b show the single number and it was the combined tax effect for a non-GAAP adjustment, as well as the use of tax attributes and other timing issues, such as NOLs. What we've done in the Q4 unaudited preliminary presentation is to break that out into two pieces, the tax provision plus the effects of the non-GAAP adjustments, as well as the tax effects of use of tax attributes and other timing items.

    重要的是,我們在表2a與2b的稅務呈現中顯示的是單一數字,該數字是非GAAP調整的合併稅務影響,以及稅務屬性運用與其他時間性議題(例如NOLs,淨營業虧損結轉)的合併效果。我們在第四季未經審計的初步簡報中所做的是把它拆成兩部分:稅費提列(tax provision)加上非GAAP調整的影響,以及運用稅務屬性與其他時間性項目的稅務影響。

  • We're reporting that the combined amount of that as 5%. Going forward, we're just going to report the tax provision, plus the effects of the non-GAAP adjustment only on T 2a and 2b. We will continue to note, in a separate table, the tax effect of tax attributes and other timing effects. So there's, as we mentioned, there's no impact on cash flow or actual taxes paid. Our approach has been to match the actual cash tax that Valeant paid each year. But again, it's been made up of those two terms which we historically combined.

    我們將其合計金額報告為5%。未來,我們在表2a與2b上只會報告稅費提列,加上非GAAP調整的影響。我們會在另一張表中持續註明稅務屬性與其他時間性影響的稅務效果。因此,如同我們提到的,這對現金流或實際繳納的稅金沒有影響。我們的做法一直是對應Valeant每年實際支付的現金稅額。但再次強調,它是由這兩個部分構成,而我們過去是把它們合併在一起。

  • - CEO

    - CEO

  • Next question, please.

    下一個問題,謝謝。

  • Operator

    Operator

  • Ram Selvaraju, HC Wainwright.

    Ram Selvaraju,HC Wainwright。

  • - Analyst

    - Analyst

  • Thanks very much for taking my question. I have two. One is in a general sense, whether you can comment on your philosophy of curtailing price increases versus what your peers in the speciality pharmaceuticals arena are doing? And how high your conviction is that going forward, this is the best approach to take given changes in the managed care environment, i.e., get rid of as many price increases as possible versus pursuing a judicious approach to maybe increasing prices on some products or not.

    非常感謝讓我提問。我有兩個問題。第一個是從整體來看,您是否能評論一下你們抑制漲價的理念,與專科藥領域同業的作法相比如何?以及在醫療保險管理環境變化之下,您對於未來採取這種作法是最佳選擇的信心有多高——也就是盡可能取消漲價,對比於採取較審慎的方式,可能對部分產品漲價或不漲價。

  • And then the second question is specific to what you previously commented on back in December regarding converting written prescriptions to filled prescriptions on Addyi. Could you give us an update on that, please?

    第二個問題是關於您先前在12月提到的,Addyi處方開立(written prescriptions)轉換為實際領藥處方(filled prescriptions)的情況。能否請您提供最新進展?

  • - CEO

    - CEO

  • Sure. So I think we've tried to be very clear on our approach to pricing, which is that going forward, and this is been in place since September, we will take single-digit price increases across some of our portfolio, in line with managed care contracts. What we made was a commitment as far as the Walgreens deal this year to reduce prices on dermatology -- WAC prices dermatology and ophthalmology, the brand products 10% this year.

    當然。我想我們一直努力把我們的定價作法講得很清楚:未來(而且自9月起已開始實施),我們會在產品組合中的部分產品採取個位數的漲價幅度,並與醫療保險管理合約保持一致。至於今年與Walgreens的合作案,我們做出的承諾是調降皮膚科——皮膚科與眼科品牌產品的WAC(批發採購成本)價格,今年下調10%。

  • We are no longer in the market for underpriced assets out there. If you actually -- WAC price increases are public knowledge and if you actually look at us versus competitors, both in the specialty and in the big pharma space, and with what WAC price increases have been this year, you will see that we're actually below what most, if not all, the other companies have done.

    我們不再去市場上尋找被低估定價的資產。如果你實際上——WAC價格調漲是公開資訊;如果你把我們與競爭對手相比,不論是在專科藥或大型藥廠領域,並看今年WAC漲價的幅度,你會發現我們其實低於大多數、甚至可能所有其他公司。

  • So I think we've talked about that and the question is how committed are we? We are very committed. In fact, that's been one of the keys in the managed care. Is that commitment and they are applauding and appreciating the approach we're taking and they're using that when they talk to other companies.

    所以我想我們已經談過這點,而問題是我們有多堅定?我們非常堅定。事實上,這一直是醫療保險管理端的一個關鍵。他們對我們的承諾表示讚賞並且認同我們採取的作法,而且他們在與其他公司溝通時也會引用這一點。

  • I think one of the very smart things that Anne and her team have done is offer something that the rest the industry has not offered yet, and that has played a big role in terms of improving overall relationships. Is that fair, Anne?

    我認為Anne和她的團隊做的一件非常聰明的事,是提供了產業其他公司尚未提供的內容,而這在改善整體關係方面扮演了重要角色。Anne,這樣說公平嗎?

  • - Company Group Chairman

    - Company Group Chairman

  • Yes, I think that's very accurate. What the payers lead, and they are very clear in this, and I understand this, after being in the industry for 25 years with other pharma companies, they want predictability. We are working with each of the payers, whether they a health plan or a PBM, on contracts around price inflation protection and as Mike said, aligning our price increases with more modest industry standards.

    是的,我認為這非常準確。付款方(payers)所主導的重點——而且他們在這點上非常明確,我也理解,因為我在其他藥廠待了25年——他們想要的是可預測性。我們正與每一個付款方合作,不論是健康保險計畫或PBM(藥品福利管理機構),在合約中加入價格通膨保護機制;並如Mike所說,讓我們的漲價幅度與較為溫和的產業標準對齊。

  • So I think you had that Addyi question. So with Addyi, you're right. We see the number of written prescriptions versus filled. And in the beginning, back in the fourth quarter we were only seeing between 25% and 30% of the prescriptions actually get paid for or filled. That number is now up to, in the most recent weeks, 57% of those prescriptions are being filled and paid for.

    我想你還有那個Addyi的問題。關於Addyi,你說得沒錯。我們會看到處方開立數與實際領藥數之間的差異。一開始,在第四季時,我們只看到約25%到30%的處方實際被付款或完成領藥。而現在在最近幾週,這個比例已上升到57%的處方被領藥並完成付款。

  • Really that sort of ramp up with a number of prescriptions is being impacted by, one, having a complex risk program. This is the first time that we're, according to our knowledge, that there been a pharmacist and physician certification process. And so really working through that has been a challenge, but we've certainly addressed it with the pharmacies. We're down to around anywhere 10% to 12% of scripts being kicked back from pharmacists.

    實際上,處方量的這種爬升受到幾個因素影響:第一,是風險管理計畫相當複雜。據我們所知,這是第一次出現藥師與醫師的認證流程。因此在推進這個流程時確實有挑戰,但我們也已與藥局端加以處理。目前大約只有10%到12%的處方會被藥師退回。

  • We're still working through the physician certification and making sure that those that are writing are certified. And part of that has to do with this is a new product and we weren't sure exactly who the targets and the writers of the product would be. We have much more clear information now on who the targets are, whose training HSDD and other diseases like that. So we're taking more targeted affect.

    我們仍在處理醫師認證的部分,並確保開立處方的醫師都已完成認證。其中一部分原因是這是一個新產品,我們一開始不確定目標族群以及會開立此產品處方的醫師會是哪些人。現在我們對目標族群有更清楚的資訊,知道哪些人正在接受HSDD(性慾低下障礙)及其他類似疾病的訓練。因此我們會採取更具針對性的作法。

  • And then lastly, the managed care process has changed dramatically, just even this past year. All of the large PBMs now [lost] new products, in most cases, from launch. They take six to nine months to actually do the clinical review and then enter into negotiations. And so it has taken us that time as we transition from Sprout to Valeant and our managed care team here picking it up, to really work through that process.

    最後,醫療保險管理流程已經大幅改變,甚至就在過去一年內。所有大型PBM現在都會[lost]新產品,在多數情況下從上市起就如此。他們需要六到九個月才能完成臨床審查,然後再進入談判。因此,當我們從Sprout轉移到Valeant、並由我們這裡的醫療保險管理團隊接手時,確實花了這段時間來把整個流程走完。

  • And I feel very confident by mid-year, we will have improved access for Addyi and we'll start to see the prescriptions that are coming through being filled and then based on the enhancements we've made to our commercial organization and filing of actual marketing materials this month to OPDP, that second half will be a much better, I think, time period, to really judge the performance of this product.

    而且我非常有信心在年中之前,我們將改善 Addyi 的可及性,並且會開始看到進來的處方被實際配藥;接著,基於我們對商業組織所做的強化,以及本月向 OPDP 提交實際行銷素材的申報,我認為下半年將會好得多,也會是一個更適合真正評估這項產品表現的期間。

  • - CEO

    - CEO

  • That being said, we take full responsibility for reduction in the -- we probably didn't move quick enough. That's my fault, but I think to Anne's point, we have not given up on this product. We've -- there's some -- clearly, we have to demonstrate our ability to have success and we have not done that yet. So that's on us. We are working hard to deliver.

    話雖如此,對於這次下調,我們承擔全部責任——我們可能行動得不夠快。這是我的錯,但我想呼應 Anne 的觀點,我們並沒有放棄這項產品。我們——有些——很明顯地,我們必須證明我們有能力取得成功,而我們目前還沒有做到。所以這是我們的責任。我們正在努力交出成果。

  • - Company Group Chairman

    - Company Group Chairman

  • And just last comment. The testimonials we hear from physicians and patients each day inspire us and every day to keep going with Addyi and really educating around HSDD. As Mike said, we haven't given up. I have a lot of confidence in this product.

    最後再補充一句。我們每天從醫師與病患那裡聽到的見證都激勵著我們,讓我們每天都持續推進 Addyi,並真正加強對 HSDD 的教育。如同 Mike 所說,我們沒有放棄。我對這項產品很有信心。

  • - CEO

    - CEO

  • All right. Next question, please.

    好的。請下一題。

  • Operator

    Operator

  • Alex Arfaei, BMO Capital Markets.

    BMO Capital Markets 的 Alex Arfaei。

  • - Analyst

    - Analyst

  • Thank you for taking the questions. Most of my questions have been asked and answered. Looking at some of your top 30 products, specifically Jublia on Solodyn, it looks like much of the Solo business isn't being made up from other channels. Could you provide your outlook for these products, specifically for Jublia, which was thought to be a growth driver? And just to follow-up on Addyi, do you still expect it a $100 million to $115 million drug in 2016?

    謝謝讓我提問。我大多數的問題都已經被問過並回答了。看你們前 30 大產品中的一些,特別是 Jublia 和 Solodyn,看起來 Solo 的業務下滑並沒有由其他通路補回。你們能否提供這些產品的展望,特別是原本被視為成長動能的 Jublia?另外追問 Addyi,你們是否仍預期它在 2016 年會是 1 億到 1.15 億美元的藥品?

  • Thank you.

    謝謝。

  • - CEO

    - CEO

  • Well, in terms of Addyi, no, we don't expect it to be $100 million to $115 million in 2016. That's one of the products that we've reduced the forecast significantly on. What we are is hopeful and if we -- we're hopeful that we will get it to that level, but certainly not in 2016.

    就 Addyi 而言,不,我們不預期它在 2016 年會達到 1 億到 1.15 億美元。這是我們已大幅下調預測的產品之一。我們所抱持的是希望——我們希望能把它做到那個水準,但肯定不是在 2016 年。

  • In terms of Jublia, it is one of the products that is -- there was a question earlier about leverage. Can you leverage your portfolio? And as Anne said, or mentioned, that derm has been one of the reviews that the managed care companies have really focused on and Jublia, in particular, so we have needed -- the net of many of our negotiations is we sacrificed the price on Jublia in order to ensure access to the rest of our portfolio.

    至於 Jublia,它是——先前有人問到「槓桿」的問題之一。你能否運用你的產品組合來談判?如同 Anne 所說或提到的,皮膚科一直是保險給付管理(managed care)公司審視的重點之一,尤其是 Jublia;因此,在許多談判中,我們的結果是:為了確保我們產品組合中其他產品的可及性,我們在 Jublia 上犧牲了價格。

  • So we would expect and we have better access for Jublia, as a result of this, than we had before. So we would expect scripts to continue to grow on Jublia. We think it's a great product, but the average price will come down. In order to return it to growth, we will really need to expand the number of scripts.

    因此,我們預期——而且因為這樣我們確實讓 Jublia 的可及性比以前更好。所以我們預期 Jublia 的處方量會持續成長。我們認為它是很棒的產品,但平均價格會下降。要讓它回到成長,我們確實需要擴大處方數量。

  • But it has been disproportionately hit in terms of managed care in order to protect, because that's what many managed care plans were looking for. Again, as Anne said, each negotiation is specific; it's not the case of every managed care plan. Every one has their own needs. But that's what we're seeing in Jublia. Next question, please.

    但就保險給付管理的影響而言,它受到的衝擊相對更大,因為為了保護其他產品——這正是許多 managed care 計畫所要求的。再次強調,如同 Anne 所說,每一次談判都是個別的;並非每一個 managed care 計畫都一樣。每一個都有自己的需求。但這就是我們在 Jublia 上看到的情況。請下一題。

  • Operator

    Operator

  • David Maris, Wells Fargo.

    Wells Fargo 的 David Maris。

  • - Analyst

    - Analyst

  • Good morning. I have a few questions. The first, Rob, why no GAAP guidance? And then a bridge to non-GAAP, since the investors could make a decision on what to include and what not to include? Second, on the text effects -- I want to get it right, use of tax attributes and other timing issues. I know a few questions have been asked about this. But does this relate to deferred tax liabilities and use of recovery of income tax, or anything else like that. I know I asked that when I met with you about a month ago. So I was just wondering if that's related to that.

    早安。我有幾個問題。第一個,Rob,為什麼沒有提供 GAAP 指引?以及能否提供一個從 GAAP 到 non-GAAP 的調節(bridge),讓投資人可以自行決定要納入哪些、排除哪些?第二個,關於稅務影響——我想確認清楚——稅務屬性(tax attributes)的使用與其他時間點議題。我知道已經有人問過一些相關問題。但這是否與遞延所得稅負債以及所得稅回收(recovery of income tax)的使用,或其他類似事項有關?我記得大約一個月前和你們見面時也問過。所以我想確認是否與那個有關。

  • And then the second half guidance seems to be a dramatic increase. Other than the inventory drawdown, is there anything else that we should expect, that should account for that? And then lastly, I think Mike, you just mentioned that launch expenses for a couple of these launches are not included in the guidance. Why would they not be included?

    另外,下半年指引看起來是大幅增加。除了庫存去化(inventory drawdown)之外,還有沒有其他我們應該預期、可以解釋這個變化的因素?最後,我想 Mike 你剛提到,幾個新產品上市的 launch 費用沒有納入指引。為什麼不把它們納入?

  • - CEO

    - CEO

  • Well, let me -- we have no launch -- until a product is approved, we don't include it in our guidance, so we don't include the revenues or the launch expenses. Now because most of our products are in -- the new launch products are in categories where we already have strong sales and marketing, the net impact of launching these products, we believe, will be neutral, at worst, in terms of our EPS.

    我先說明——在產品獲准之前,我們不會把上市相關內容納入指引,因此不會納入營收或上市費用。另外,由於我們大多數新上市產品都在我們既有強勢銷售與行銷的類別中,我們相信推出這些產品的淨影響,最差情況下,對我們的 EPS 也會是中性的。

  • So this just the way we treat it. We don't put in the revenues and we don't put in the costs, because they are not approved yet. And that's always been what we've -- that's always been the approach we've taken to guidance, and at least from our vantage point, that make sense, is -- . To include revenues and not costs wouldn't make sense. To improve the costs but not the revenues wouldn't make sense. So we choose not to include either. Rob --

    這就是我們的處理方式。我們不把營收放進去,也不把成本放進去,因為它們尚未獲准。這一直是我們對指引所採取的方法,至少從我們的角度來看,這樣做是合理的——。把營收納入但不納入成本不合理。把成本納入但不納入營收也不合理。所以我們選擇兩者都不納入。Rob——

  • - Analyst

    - Analyst

  • But is it fair -- just as a follow-up to that, Mike, is it fair to say that if they're approved, since products aren't usually profitable in the first year or two, that we'd see an increase in the expenses just for the launch expenses? Not for the infrastructure or the new salespeople, but just for launch expenses?

    但就此追問一下,Mike,這樣說是否公平:如果它們獲准,因為產品通常在前一兩年不會獲利,我們會看到費用增加,主要是上市費用的增加?不是基礎建設或新增業務人員,而只是上市費用?

  • - CEO

    - CEO

  • For the net -- our belief, at least for the products this year, we would not expect it to have an impact on overall guidance, for example, if that's the question. So we will have ophthalmology, we hope to get approved --

    就淨影響而言——至少就今年的產品來看——我們不預期它會影響整體指引;如果你的問題是這個的話。所以我們在眼科方面,希望能獲准——

  • - Company Group Chairman

    - Company Group Chairman

  • I believe it is July

    我認為是在七月。

  • - CEO

    - CEO

  • July. We believe we will have enough revenues to cover any of the launch expenses, and Broda, we do not expect to get approved til November/December. So again, it should have minimal impact on our guidance. So we don't expect to be taking down guidance until we get products approved. Is that --so Rob?

    七月。我們相信會有足夠的營收來覆蓋任何上市費用;而 Broda 我們預期要到 11 月/12 月才會獲准。因此,同樣地,它對我們指引的影響應該很小。所以在產品獲准之前,我們不預期會下調指引。是這樣——所以 Rob?

  • - CFO

    - CFO

  • I'll take your question first, tax effects are largely NOLs, and the use of deferred tax assets, not liabilities. With respect to the GAAP guidance, as we explained in the footnote of the press release, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary to do it, we find it more accurate and better for our investors to guide to the non-GAAP measures that we do.

    我先回答你的第一個問題:稅務影響主要是 NOL(淨營運虧損結轉),以及遞延所得稅資產的使用,而不是遞延所得稅負債。至於 GAAP 指引,如同我們在新聞稿註腳中所解釋的,由於在預測與量化某些為編製 GAAP 指引所必須的金額時存在固有困難,我們認為以我們所提供的 non-GAAP 指標作為指引,對投資人而言更精準也更有幫助。

  • - CEO

    - CEO

  • Next question, please.

    下一個問題,請。

  • Operator

    Operator

  • Luca Salvero, Neumann Capital.

    Luca Salvero,Neumann Capital。

  • - Head of IR

    - Head of IR

  • Next question, please.

    下一個問題,請。

  • Operator

    Operator

  • Alan Ridgeway, Scotiabank.

    Alan Ridgeway,豐業銀行(Scotiabank)。

  • - Analyst

    - Analyst

  • Hi, good morning. Thanks for taking the questions.

    嗨,早安。謝謝讓我提問。

  • I just have question about the bridge to the 2016 guidance. I'm trying to just get a feel for your reduced revenue expectations for both the derm and the Salix business and then the managed care contracting piece, as well.

    我只有一個關於銜接到 2016 年財測指引的問題。我想大致了解一下你們對皮膚科與 Salix 業務的營收預期下修,以及受管理式醫療(managed care)合約影響的部分。

  • Can you speak to in your reduced expectations from a revenue perspective this year, what the split between volume declines, or decline in your expectations for demand versus your expectations on pricing? And then how that may have changed in the last little while, as you've contracted with managed care, and I'll leave it at that. Thanks.

    能否談談今年從營收角度來看,你們下修預期中,量的下滑(或對需求的預期下降)與價格預期之間的分拆各占多少?另外,隨著你們與管理式醫療簽約,這在最近一段時間可能有何變化?我就問到這裡。謝謝。

  • - CEO

    - CEO

  • Great. Well, the managed care is just all price, right? That's -- we've quantified that. Hopefully, what we hope to be able to do is to with this better access is actually drive more volume. We have not built a lot of that into our forecast and that should be upside. But in terms of managed care, that is basically price.

    好的。管理式醫療那部分其實完全是價格因素,對吧?我們已經把它量化了。我們希望透過更好的給付可近性(access)實際上能帶動更多量。我們在預測中並沒有把太多這部分納入,因此那應該會是上行空間。但就管理式醫療而言,基本上就是價格。

  • In terms as we think about prices captured there, obviously, with -- there is some price in the revenue side. Ex -- not the managed-care piece, partly through the price reductions that we're giving in ophthalmology and dermatology, as well as the fact that we are sort of price increases, we're more limited in what we can do. In some cases, some of the commitment to managed-care was to keep price increases lower than we have historically so there's a price element.

    至於我們所掌握的價格面,顯然在營收端也有一些價格因素。例如——不是指管理式醫療那一塊——部分來自我們在眼科與皮膚科所提供的降價,以及我們在調漲價格方面能做的事情更受限制。在某些情況下,對管理式醫療的部分承諾,是把漲價幅度維持在低於我們過去的水準,因此確實存在價格因素。

  • We actually, and then there's first quarter where demand has been lower. But we do expect, if you actually look at the scripts, we're running ahead of last year in dermatology and so we are quite pleased with that. We are seeing -- experiencing great script growth in the GI franchise.

    此外,第一季需求確實較弱。但我們預期,如果你實際看處方量(scripts),皮膚科目前是領先去年同期的,因此我們對此相當滿意。我們也看到——在腸胃(GI)產品線正經歷很強的處方成長。

  • In terms of ophthalmology, again, there we have a decrease in scripts, but we're increased in share in the branded portion and those are the three main franchises. So, overall, we expect demand to continue to increase over the course of the year. Next question.

    至於眼科,同樣地,我們的處方量有所下降,但在品牌藥(branded)那一部分的市占率是提升的;這三個是主要產品線。因此整體而言,我們預期需求在今年接下來的期間會持續增加。下一個問題。

  • Operator

    Operator

  • Gregg Gilbert, D.B.

    Gregg Gilbert,D.B.。

  • - Analyst

    - Analyst

  • Thank you.

    謝謝。

  • First, Mike, when you talk about script growth for derma, are you talking about scripts of IMS plus Philidor, so i.e., real prescriptions, or just those that we see on IMS, which might be inflated due to the Walgreens shift away from Philidor?

    第一個問題,Mike,你提到皮膚科處方成長時,指的是 IMS 加上 Philidor 的處方,也就是實際處方量?還是僅指我們在 IMS 上看到的處方量——那可能因 Walgreens 從 Philidor 轉移而被放大?

  • Secondly, when do you expect to be able to file the 10-K and can you share your game plan with us? I.e., what is in your control? What is in the Board's control, or gated by the Board? And are your auditors in agreement with your game plan and your timeline? I suspect a lot of people are going to wonder after this call when you expect to get the K done and all the implications that come with that.

    第二,你們預期何時能提交 10-K?能否跟我們分享你們的行動計畫?也就是,哪些在你們管理層可控範圍內?哪些在董事會可控範圍內,或需要董事會把關?你們的審計師是否同意你們的計畫與時程?我想很多人在這通電話後會想知道你們何時能完成 10-K,以及隨之而來的所有影響。

  • And lastly, Mike, can you comment on the situation, specifically with Deb and Tanya, given that we only have media reports to rely on and clearly, you know at a personal level, what happened in those cases.

    最後,Mike,你能否評論一下相關情況,特別是關於 Deb 和 Tanya?因為我們只能依賴媒體報導,而顯然你在個人層面知道那些案例發生了什麼。

  • Thanks very much.

    非常感謝。

  • - CEO

    - CEO

  • Okay, so script growth, Ari, do you want to --

    好,關於處方成長,Ari,你要不要——

  • - Company Group Chairman

    - Company Group Chairman

  • Derma is running year to date roughly 10% ahead of last year, all in. We are now using Symphony IDB data, so just so you know that's what we're going to be tracking. So far, all in, derma is growing the access program is still relatively new, as Mike described, and we're expanding into networks and independents, so we will continue to expect good TRX growth through the course of the year.

    皮膚科年初至今整體約比去年同期高 10%。我們現在使用 Symphony IDB 數據,所以讓你知道,我們接下來會追蹤這個指標。到目前為止,整體而言皮膚科仍在成長;如 Mike 所述,可近性方案(access program)仍相對新,我們也正在擴展到連鎖通路與獨立通路,因此我們預期今年接下來 TRX 仍會有不錯的成長。

  • - CEO

    - CEO

  • In terms of the 10-K. Certain things are within our control and certain things aren't, as management. We have the ad hoc committee continuing to do their review. So partly depends on that; partly depends on us. We have to do our work in terms of submitting a 10-K. And then we are in constant conversations with PWC in terms of they have to do their work.

    至於 10-K。有些事情在我們管理層的控制範圍內,有些則不在。臨時(ad hoc)委員會仍在持續進行審查。因此部分取決於他們;部分取決於我們。我們必須完成提交 10-K 所需的工作。同時我們也與普華永道(PWC)保持持續溝通,因為他們也必須完成他們的工作。

  • That's the best estimate that I can give but again, we don't control it -- it's -- we hopefully get this 10-K filed sometime in April. But I can't commit to that. But that would be my best estimate of -- based on everything that I know.

    這是我能給的最佳估計;但再次強調,我們無法完全掌控——我們希望能在 4 月某個時間提交 10-K。但我無法對此做出承諾。不過以我所知的一切來看,這會是我對時程的最佳估計。

  • In terms of Deb and Tanya. Deb, as we said, resigned. She was a valued employee. She led a lot of the marketing initiatives. She led our derm business and did a great job. We were disappointed that she left. As I mentioned, she was part of the EMT, where we had no retention in place, so because they are executive officers of the Company. We wish her well and we were quite clear that had nothing do with the ad hoc committee or anything else; it was a decision that she made.

    至於 Deb 和 Tanya。Deb 如我們所說,已經辭職。她是一位很受重視的員工。她主導了許多行銷計畫。她帶領我們的皮膚科業務並且做得非常好。我們對她離開感到遺憾。如我提到的,她是 EMT 的一員,而我們對該層級沒有留任安排,因為他們是公司的執行主管(executive officers)。我們祝福她,也很清楚地說明這與臨時委員會或其他任何事情無關;這是她自己做出的決定。

  • And then Tanya. Again, that happened when I wasn't here, so I can't comment on the Tanya -- I don't have information on that so I can't comment on that.

    至於 Tanya。同樣地,那是在我不在的時候發生的,所以我無法評論 Tanya 的情況——我沒有相關資訊,因此無法評論。

  • - Analyst

    - Analyst

  • Thanks.

    謝謝。

  • Operator

    Operator

  • David Steinberg, Jefferies.

    David Steinberg,Jefferies。

  • - Analyst

    - Analyst

  • Thank you. You mentioned destocking quite a few times on the call, in particular, for some your key brands. I was wondering if you could help us with inventory levels. I believe in the past, you said normal levels in the US were about two to six weeks and two to four months globally. Are -- can you confirm you're within that normal range, and perhaps pinpoint in the United States, given the last public forum, are you higher or lower than you were last time you spoke to the investment community?

    謝謝。你們在電話會議中多次提到去庫存(destocking),特別是針對一些關鍵品牌。我想請你們協助說明庫存水位。我記得你們過去曾說,美國正常水位約為 2 到 6 週,全球約為 2 到 4 個月。你們能否確認目前仍在該正常區間內?另外就美國而言,鑑於上一次公開場合,你們目前相較於上次與投資社群溝通時,是更高還是更低?

  • Secondly, Valeant has benefited from the lowest tax rate in your industry. I was just curious. Could you remind us how long that tax rate is ironclad? There's a tax treaty. If there's a period of time when it will be reviewed and if -- when that time is?

    第二,Valeant 一直受惠於你們產業中最低的稅率。我只是好奇。你能否提醒我們這個稅率能被「鎖死」(ironclad)多久?有一項稅務條約。是否有一個期間會被重新檢視?如果有——那會是在什麼時候?

  • And then lastly, bigger picture question, Mike. On your corporate culture, do you think elements of it need to change? Do you think there's some components that incentivize sub-optimal behavior? And then could you comment on, are there any changes that -- the top-level management was not part of the retention plan. Have there been any changes to the compensation package? Thank you.

    最後一個較宏觀的問題,Mike。關於你們的企業文化,你認為其中一些元素需要改變嗎?你認為是否有某些組成部分會誘發非最優(sub-optimal)的行為?另外你能否評論一下,最高層管理團隊並未納入留任計畫。薪酬方案是否有任何變更?謝謝。

  • - CEO

    - CEO

  • So in terms of compensation package, there's been no changes in terms of the senior management. In terms of inventory levels, those continue to be our guidelines: two to six and four, outside of that. Although that varies by country. Gregg, I think we've been completely flat in terms of inventory levels in terms of the US. Outside the US, I think actually inventories have been down a little bit.

    因此就薪酬方案而言,高階管理層方面沒有任何變動。就庫存水位而言,仍然遵循我們的指引:兩到六週,以及四週(超出該範圍則另當別論)。不過這會因國家而異。Gregg,我認為就美國而言,我們的庫存水位一直完全持平。在美國以外,我認為實際上庫存略有下降。

  • But so no changes in inventory levels. Since the volume has increased through Walgreens, that -- in terms of absolute dollars, that means our inventory levels have come down, because what we're talking about that flat, we're talking about in terms of weeks. Since Walgreens is consignment, the absolute level of distributor inventories in the US for dermatology, for example, has come down, although the weeks have remained in the same. So hopefully, that's clear.

    所以庫存水位沒有變化。由於透過 Walgreens 的銷量增加——就絕對金額而言——這表示我們的庫存水位下降了,因為我們所說的持平,是以週數來衡量。由於 Walgreens 採寄售模式,例如在美國皮膚科領域,經銷商庫存的絕對水位已經下降,儘管週數仍維持不變。希望這樣說明清楚。

  • In terms of tax rate, we do not know of any imminent or any changes that are coming down. So again, we will see that space on governments. But we were unaware of anything that would change our tax rate.

    就稅率而言,我們不知道有任何迫在眉睫或即將到來的變更。所以同樣地,我們會持續關注各國政府在這方面的動向。但我們並未察覺有任何會改變我們稅率的事項。

  • In terms of -- we've talked about bolstering -- in terms of corporate culture. It's interesting, when we meet with AIP, I think there's a couple variables that we are investing in. We will continue to try to upgrade our financial reporting, certainly from a PR and government relations side.

    就——我們談到要強化——企業文化而言。有趣的是,當我們與 AIP 會面時,我認為有幾個變數是我們正在投入的。我們將持續努力提升我們的財務報導,當然也包括公關與政府關係層面。

  • We are committed to investing or in the process of investing in those functions. As, we said in the press release, we are, as all pharma companies do, we are continuing to emphasize compliance. We are continuing to emphasize, from a quality standpoint, and continuing to fill that capability quite a bit. I think we've almost more than doubled our quality department, corporate in the US. We make big investments in quality in terms of headcount and capability and we feel very good about that. We will -- so we've grown pretty quickly.

    我們致力於投資,或正處於投資這些職能的過程中。正如我們在新聞稿中所說,和所有製藥公司一樣,我們持續強調合規。我們也持續強調品質面向,並且持續大幅補強這項能力。我想我們在美國的公司層級品質部門幾乎已經增加到兩倍以上。我們在品質方面投入大量資源,包括人力編制與能力建置,對此我們感到非常有信心。我們將——因此我們成長得相當快。

  • We are going to continue to invest in the core functions to make sure that we deliver high-quality products to physicians and to patients and work in the most compliant way in the US and beyond the US.

    我們將持續投資核心職能,以確保我們向醫師與病患提供高品質產品,並在美國及美國以外以最合規的方式運作。

  • Next question, please.

    請下一個問題。

  • Operator

    Operator

  • Randy Raisman, Marathon Asset Management.

    Randy Raisman,Marathon Asset Management。

  • - Analyst

    - Analyst

  • Hello guys.

    各位好。

  • How are you doing? Can you just provide us a little bit of a bridge on the cash balance? Because when we look at it, we see you had roughly $600 million of cash at Q4; it looks like you drew down $1.2 billion on the revolver, so it will take you to $1.8 billion. You paid $900 million between the -- for the term loan and then there was another payment that you made.

    你們好嗎?你們能否就現金餘額提供一點銜接說明(bridge)?因為我們看起來,你們在第四季約有 6 億美元現金;看起來你們從循環信貸(revolver)提用了 12 億美元,這會使你們到 18 億美元。你們在——定期貸款(term loan)方面支付了 9 億美元,然後還有另一筆你們支付的款項。

  • So that should left you with about $900 million of cash, and you're saying you have $1.2 billion of cash so that would imply then that you generated $300 million of cash in the first quarter and that doesn't really line up with the guidance for $2.2 billion of cash flow for the year.

    所以那樣應該會讓你們剩下大約 9 億美元現金,但你們說你們有 12 億美元現金,因此這意味著你們在第一季產生了 3 億美元現金,但這與全年 22 億美元現金流指引似乎對不上。

  • How do we get comfortable that you're going to generate an extra $1 billion of cash than where you're currently running?

    我們如何能放心你們會比目前的運行水準多產生額外 10 億美元的現金?

  • - Treasurer

    - Treasurer

  • On the revolver, we ended the year with $250 million drawn on the revolver and we're now at $1.45 billion. We obviously are generating cash in the first quarter. We did have, however, some large payments in the first quarter that we discussed. $500 million for Sprout that we talked about.

    在循環信貸方面,我們在年底時循環信貸提用額為 2.5 億美元,而現在是 14.5 億美元。顯然我們在第一季有產生現金。不過,我們在第一季確實有一些我們已討論過的大額付款。包括我們提到的 Sprout 5 億美元。

  • We paid early; they were not due until April 20, $260 million of maturities. I mentioned the excess cash flow payment of about $100 million, which we will be due at the end of March 31. And those are some of the big payments. But again, we -- without these large payments, we were generating cash this quarter.

    我們提前支付了原本要到 4 月 20 日才到期的 2.6 億美元到期款。我也提到約 1 億美元的超額現金流付款(excess cash flow payment),這筆款項將於 3 月 31 日到期。這些是一些主要的大額付款。但再說一次——若沒有這些大額付款,我們本季其實是在產生現金的。

  • - Analyst

    - Analyst

  • Right. But my question is based on my math, it looks like you generated maybe $300 million of cash quarter to date from what you've disclosed, and you're telling us we should think you're going to generate $2.2 billion of cash for the year. So where is the ramp going to come from, from Q1? That's a big jump.

    了解。但我的問題是,按我的計算,從你們披露的資訊看起來,你們截至目前可能只產生了約 3 億美元現金,而你們告訴我們全年應該產生 22 億美元現金。那麼從第一季開始,後續的增幅(ramp)會從哪裡來?這是很大的跳升。

  • - CEO

    - CEO

  • It is, but we took down revenue in Q1 considerably because of -- we've gone through that explanation in starting in Q2 and Q3 and Q4. Cash generation will be stronger than it has been in Q1.

    確實如此,但我們在第一季大幅下調了營收,原因是——我們已經解釋過,從第二季、第三季到第四季會逐步反映。現金產生能力會比第一季更強。

  • - Treasurer

    - Treasurer

  • That is correct. Obviously, cash generation depends on working cap, so we're not quite done with the quarter, so that's going to impact. I can't confirm, specifically, but it's exactly $300 million, but you should think of it as cash generation before these type of payments.

    沒錯。顯然,現金產生取決於營運資金(working cap),而我們本季尚未完全結束,因此這會造成影響。我無法具體確認是否正好是 3 億美元,但你應該把它視為在扣除這類付款之前的現金產生。

  • - Analyst

    - Analyst

  • And then just on a leverage covenants, so if you're look at 2.1 times and the covenant is 2.5, is that something you're going to look to amend, as well, when you go out to the bank group, because there's not that big of a cushion there.

    另外關於槓桿比率的財務契約(leverage covenants),如果你們看的是 2.1 倍,而契約上限是 2.5 倍,你們在與銀行團洽談時是否也會考慮修訂?因為緩衝空間並不大。

  • - Treasurer

    - Treasurer

  • Right now per what we spoke about before, we're thinking about amending or we going to amend for cross-default, as well as timing.

    目前依照我們先前談到的,我們考慮要修訂或將會修訂的是交叉違約(cross-default),以及時間安排。

  • - Analyst

    - Analyst

  • Okay.

    好的。

  • - Treasurer

    - Treasurer

  • We've done stress cases on our covenants, based on our guidance. And we are comfortable, as we said in the past.

    我們已根據指引對我們的財務契約做過壓力情境測試(stress cases)。而且我們如同過去所說,對此感到放心。

  • - Analyst

    - Analyst

  • Great. Thank you.

    很好。謝謝。

  • Operator

    Operator

  • Irina Koffler, Mizuho.

    Irina Koffler,Mizuho。

  • - Analyst

    - Analyst

  • Thanks for taking the question. Just curious -- sorry, phone issues. What would you do in the future once your business is normalized? I mean is it more going back to buying additional assets. You mentioned you're not going to buy inexpensive or mispriced assets in the future, but what can we look for from the Company once this period blows over.

    謝謝讓我提問。只是好奇——抱歉,電話有點問題。未來當你們的業務恢復正常後,你們會怎麼做?我的意思是,是否會更偏向回到收購更多資產?你們提到未來不會收購便宜或被錯價的資產,但當這段期間過去後,我們可以期待公司會有哪些動作?

  • Thanks.

    謝謝。

  • - CEO

    - CEO

  • We are going to work hard to get this period to blow over. We're going to reduce our debt. We've made a commitment to get under 4 times. Until we get under 4 times, we will -- we're not looking to make any acquisitions, so that's our -- we are excited about our launch products. We're excited about many of our products, that we've recently launched, like Ultra and Biotrue and we want to demonstrate we can drive growth with our current portfolio, and our R&D pipeline, which we feel that we can.

    我們會努力讓這段期間盡快過去。我們會降低負債。我們已承諾要把槓桿降到 4 倍以下。在降到 4 倍以下之前,我們——不打算進行任何收購,所以這就是我們的——我們對我們的上市新品(launch products)感到振奮。我們也對許多近期上市的產品感到振奮,例如 Ultra 和 Biotrue;我們希望證明我們能以現有產品組合以及我們的研發管線帶動成長,而我們也相信我們做得到。

  • If we fast forward to the period, through that period, which is probably a long time from now, then we will continue to look for assets that fit into probably the areas where we have strengths today, which will be dermatology, ophthalmology, GI and emerging markets. But as you mentioned, we will not be looking at acquisitions that involve sort of the mispriced assets that will not be part of our agenda.

    如果我們把時間快轉到那段期間之後——那可能是很久以後的事——那麼我們會持續尋找能融入我們目前強項領域的資產,這些領域可能包括皮膚科、眼科、腸胃科(GI)以及新興市場。但如你所提到的,我們不會考慮涉及所謂錯價資產的收購,那不會是我們議程的一部分。

  • - Analyst

    - Analyst

  • Okay. Thanks.

    好的。謝謝。

  • - CEO

    - CEO

  • Next question, please.

    請下一題。

  • Operator

    Operator

  • David Common, JPMorgan.

    David Common,摩根大通。

  • - Analyst

    - Analyst

  • Terrific. Thanks for the fixed income question opportunity. My question relates to any non-core assets sold. Can you tell us whether you are currently required or expect to be required to pay off secured debt with those assets? To the extent that you've given us an expected debt reduction for 2016, does that presume any asset sales?

    太好了。謝謝讓我有機會提固定收益方面的問題。我的問題與任何已出售的非核心資產有關。你們能否告訴我們,針對這些資產,你們目前是否被要求、或預期將被要求用其來償還擔保債務?就你們已提供的2016年預期減債幅度而言,是否假設會有任何資產出售?

  • And also, you previously, I believe, plan to pay off, I think it was $800 million you had in your revolver at December in addition to a, I believe, $2.25 billion of other debt. Could you tell us what your expectations are for reduction and the revolver balance over the next 12 months, or in this fiscal year? Thank you.

    另外,我記得你們先前計畫償還,我想是12月時你們循環信貸(revolver)上的8億美元,此外還有我想是22.5億美元的其他債務。你們能否談談未來12個月、或在本財政年度內,對於減債以及循環信貸餘額的預期?謝謝。

  • - Treasurer

    - Treasurer

  • Sure, David, first on asset sales, to our private agreement, we have 365 days that we could reinvest the proceeds. But as Mike said, we are very focused on debt paydown. So, I expect we will use some of those proceeds to pay down debt further. Secondly, the $1.7 billion that I mentioned in the slide is permanent debt reduction.

    當然,David,先談資產出售。依照我們的私下協議,我們有365天可以將出售所得再投資。但如Mike所說,我們非常專注於償還債務。因此,我預期我們會用其中一部分所得進一步償債。第二,我在投影片中提到的17億美元是永久性減債。

  • It doesn't include any additional debt reduction we would do from asset sales. And to answer your third question, going back to the JPMorgan slides, and I know exactly what you're referencing on the $825 million. That $825 million was paying down year-end revolver balance, as well as discretionary cash. The year-end revolver balance was $250 million, so I did want to clarify that, that wasn't implying we were going to pay down $825 million of revolver.

    這不包含我們可能因資產出售而進行的任何額外減債。至於你的第三個問題,回到摩根大通的投影片,我很清楚你指的是8.25億美元。那8.25億美元是用來償還年末循環信貸餘額,以及動用可自由支配的現金。年末循環信貸餘額是2.5億美元,所以我想澄清一下,這並不表示我們要償還8.25億美元的循環信貸。

  • Lastly, we are committed to the $1.7 billion of permanent debt. We also want to bring the revolver balance down significantly, but through the course of the year, but I don't want to commit right now that it will be zero at the end of the year.

    最後,我們承諾要完成17億美元的永久性減債。我們也希望在一年過程中大幅降低循環信貸餘額,但我現在不想承諾年底會降到零。

  • - Analyst

    - Analyst

  • Perfect. Thank you.

    完美。謝謝。

  • Operator

    Operator

  • Tim Chiang, BTIG.

    Tim Chiang,BTIG。

  • - Analyst

    - Analyst

  • Hi, Mike. I had one follow-up. I know that you guys had said that you were going to lower your cost structure on the SG&A set for some of these niche divisions, whether it's Solta, Obagi. I know that these groups have been pretty -- they've been run pretty lean already. I'm just wondering how much additional cost-cutting can you really do in these types of groups here?

    嗨,Mike。我有一個追問。我知道你們曾說過,會在某些利基事業部(不論是Solta、Obagi)降低SG&A的成本結構。我知道這些團隊一直都相當精實——運作得已經很精簡了。我只是想知道,在這類團隊裡,你們實際上還能再做多少額外的成本削減?

  • - CEO

    - CEO

  • I think we talked about cost reduction, both in terms of some of the smaller businesses, but we also had to step back and look at the overall SG&A, which, as a percent, has increased and we have to take a look at that with, again, the caveating of reinventing core functions that we want to build capabilities in.

    我想我們談到的降本,既包括一些較小的業務,但我們也必須退一步檢視整體SG&A;以占比來看,它已經上升了,我們必須檢視這點,同時也要再次提醒,我們正在重塑核心職能,並希望在其中建立能力。

  • Some of these expenses, quite frankly, have grown some of these smaller businesses. And as Ari mentioned, we're not in the business of running unprofitable businesses. So Solta, we are taking steps to make sure it's profitable and delivering cash flow to our investors. So it's not like Solta, there will be cost reduction. We are spending too much in terms of, relative to the revenues in the US.

    坦白說,其中一些費用是為了推動這些較小業務的成長而增加的。而如Ari提到的,我們不做虧損的生意。因此,對Solta而言,我們正在採取措施,確保它能獲利並為投資人帶來現金流。所以並不是說Solta不會降本;相對於美國的營收而言,我們的支出確實過高。

  • Obagi is a different issue; it's more around sales. It's making money and there, it's focusing on and increasing the growth rates. We have a great franchise there, et cetera. In terms of businesses like Commonwealth, we had a plan to expand sales and marketing quite a bit. The demand is slower. It is growing.

    Obagi是不同的議題;更多是在銷售端。它是賺錢的,而我們在那裡的重點是提升成長率。我們在那裡有很好的品牌/事業基礎,等等。至於像Commonwealth這類業務,我們原本有一個大幅擴張銷售與行銷的計畫。需求較慢。它仍在成長。

  • It continues to grow, which is positive. But we are not going to increase spending at the same rate that we were planning on increasing spending. We are going to be more moderate in terms of our approach and as the revenues build, then we'll continue to invest. But we'll do it in a profitable way.

    它持續成長,這是正面的。但我們不會以原先計畫的同樣速度增加支出。我們會採取較為溫和的方式;隨著營收建立起來,我們會繼續投資。但我們會以能獲利的方式來做。

  • It's the same approach as launching any new product. You can choose to spend a lot of money in the short-term, and in hopes of accelerating revenue, or you could take a more measured approach, and that's what we're going to do in these businesses to ensure that we continue to grow the businesses, but we also continue to put dollars to the bottom line.

    這與推出任何新產品的做法相同。你可以選擇在短期內花很多錢,期望加速營收;或者採取更審慎、循序漸進的方式,而這就是我們在這些業務上要做的,以確保我們持續成長,同時也能把更多金額落到淨利。

  • - Analyst

    - Analyst

  • Mike, just one follow-up. I think back in December, you had originally thought -- this is on Xifaxan, by the way, that you were originally going to hire another 100 reps to support Xifaxan's growth in HE; is that still part of the plan in 2016?

    Mike,再追問一個。我記得去年12月時,你們原本想——順帶一提這是關於Xifaxan——你們原本打算再招募100名業務代表來支持Xifaxan在HE方面的成長;這仍是2016年的計畫之一嗎?

  • - CEO

    - CEO

  • Yes. It's on that -- as Ari, I think mentioned earlier, those reps have been hired and trained. When do they get on the field, Ari?

    是的。就那部分——我想Ari先前也提到,那些業務代表已經招募並完成訓練。Ari,他們什麼時候會上線到前線?

  • - Company Group Chairman

    - Company Group Chairman

  • In the next couple of weeks, they will be --

    在接下來幾週內,他們會——

  • - CEO

    - CEO

  • Next couple of weeks, so certainly by second quarter. But we have -- by the end of the second quarter, up running and fully trained. That has not changed.

    接下來幾週內,所以肯定會在第二季。但我們會——到第二季末時,已經上線運作並完成全部訓練。這點沒有改變。

  • - Analyst

    - Analyst

  • Okay. Thanks.

    好的。謝謝。

  • Operator

    Operator

  • Derek McGirt, Marathon.

    Derek McGirt,Marathon。

  • - Analyst

    - Analyst

  • Thank you. My question has been answered.

    謝謝。我的問題已經被回答了。

  • - CEO

    - CEO

  • Thank you. Next question.

    謝謝。下一題。

  • Operator

    Operator

  • Cindy Quan, Goldman Sachs.

    Cindy Quan,高盛。

  • - Analyst

    - Analyst

  • Hi, thank you. I wanted to ask, have you bought back any bonds in 4Q or 1Q in the open market? I think I saw the senior note balance is about $35 million lower from 3Q but is that just translation for the Euro tranche or was any debt bought back on the senior note side? Thanks.

    嗨,謝謝。我想問,你們在第四季或第一季是否有在公開市場回購任何債券?我想我看到高級票據(senior note)餘額相較第三季少了約3,500萬美元,但那只是歐元券種的匯率換算影響,還是你們在高級票據方面有回購任何債務?謝謝。

  • - Treasurer

    - Treasurer

  • Cindy, note that has been bought back in the open market for bonds and you're absolutely correct, that it would be translation. Because the Euro bond needs to be marked to those current FX rates.

    Cindy,公開市場並沒有回購任何債券;你說得完全正確,那會是匯率換算。因為歐元債需要按當前匯率重新換算。

  • - Analyst

    - Analyst

  • Any comment in 1Q, if there was any debt bought back?

    那第一季方面,有沒有任何回購債務的評論?

  • - Treasurer

    - Treasurer

  • No. There have been no bonds bought back in 1Q to date.

    沒有。截至目前,第一季沒有回購任何債券。

  • - Analyst

    - Analyst

  • Thanks.

    謝謝。

  • Operator

    Operator

  • David Maris, Wells Fargo.

    David Maris,富國銀行。

  • - Analyst

    - Analyst

  • Sorry about that.

    抱歉,剛剛那樣。

  • Mike, one of the questions that an investor asked me to ask has to do with the speed of the business and the decline of the market cap and all the rest. They had seen that in a news report, that the Board had thought of bringing in a new CEO, a new management team to start things afresh but one of the pushbacks was that there was a large parachute or downstream payments.

    Mike,有位投資人請我代問的一個問題,與業務進展速度、市值下滑以及其他相關情況有關。他們在一則新聞報導中看到,董事會曾考慮引進新的CEO、以及新的管理團隊來重新開始,但其中一個反對意見是存在一筆很大的「降落傘」或後續支付款項。

  • Is that true to your knowledge? And second, are you -- given the way the Philidor thing and all the rest has played out so far, are you willing, if the Board said to, that they wanted to bring in a new management team to forego those, what are sometimes called golden parachute payments.

    就您所知,這是真的嗎?第二,鑑於 Philidor 事件以及到目前為止其他一切的發展情況,如果董事會表示他們希望引進新的管理團隊,您是否願意放棄那些有時被稱為「黃金降落傘」的補償金?

  • - CEO

    - CEO

  • I'm not aware of a golden parachute payment, so --

    我不知道有所謂的黃金降落傘補償金,所以——

  • - Analyst

    - Analyst

  • Any termination-related payments.

    任何與終止聘僱相關的付款。

  • - CEO

    - CEO

  • Again, I don't think -- I'm not sure. I don't know if everything in that article was correct; I wasn't on the Board. So I can't speak to that. I do not -- maybe I should wish I could get $200 million if I leave but unfortunately, I don't think that's the case. Fortunately, from an investor standpoint, it's not the case.

    再說一次,我不認為——我不確定。我不知道那篇文章裡的內容是否都正確;我當時不在董事會。所以我無法就此發言。我不——也許我應該希望如果我離開能拿到 2 億美元,但不幸的是,我不認為是那樣。從投資人的角度來看,幸好也不是那樣。

  • Actually, I think I'm pretty modest. If I got fired, it is pretty modest. They may be referring to some stock that is vested that's not delivered until the future, but that's been divested. That was -- so David, I'm not aware of any golden parachute that I have.

    其實,我覺得我相當節制。如果我被解雇,補償是相當有限的。他們可能指的是一些已歸屬但要到未來才交付的股票,但那已經被處分了。那是——所以 David,我不知道我有任何黃金降落傘。

  • - Analyst

    - Analyst

  • Okay. Thank you for clearing that up.

    好的。謝謝你澄清。

  • Operator

    Operator

  • Henry Reukauf, Deutsche Bank.

    Henry Reukauf,德意志銀行。

  • - Analyst

    - Analyst

  • Just had a quick question on the forward-looking guidance for the next 12 months. I think you said it's going to be $6 billion instead of $6.2 billion to $6.4 billion that was in the press release today. Did I hear that correctly? If I did, what's the reason for the change? And one more after that.

    我對未來 12 個月的前瞻性指引有個簡短問題。我想你說會是 60 億美元,而不是今天新聞稿裡的 62 億到 64 億美元。我聽得對嗎?如果是,變更的原因是什麼?之後我還有一個問題。

  • - CFO

    - CFO

  • The current was correct and what was in the press release was an error.

    目前的數字是正確的,而新聞稿裡的是錯誤。

  • - Analyst

    - Analyst

  • Was it -- it definitely looks like it was switched kind of intentionally? Is there -- was there any other further comment on that or no?

    那是——看起來確實像是刻意對調了?對此還有——是否有任何進一步評論,還是沒有?

  • - CEO

    - CEO

  • No, it wasn't switch intentionally. It was just a wrong number and we apologize.

    不,並不是刻意對調。只是數字寫錯了,我們致歉。

  • - Analyst

    - Analyst

  • Okay. And then the last one is just on the debt, you want to get to debt to 4 times. You mentioned no more acquisitions; does that also include share repurchases? So can we assume that basically all the free cash flow is going to repay debt?

    好的。最後一個問題是關於負債,你們希望把負債降到 4 倍。你提到不再進行併購;這也包括庫藏股回購嗎?所以我們可以假設基本上所有自由現金流都會用來償還負債嗎?

  • - CEO

    - CEO

  • Again, that's probably our current intent is to do that. We reserve the right to change that but what we are 100% committed to is reducing debt to 1.7. And our focus is on debt repaid down.

    再說一次,那大概是我們目前的意圖。我們保留改變的權利,但我們 100% 承諾的是把負債降到 1.7。我們的重點是償還並降低負債。

  • - Analyst

    - Analyst

  • Thanks a lot.

    非常感謝。

  • Operator

    Operator

  • Dmitry Khmelnitsky, Veritas.

    Dmitry Khmelnitsky,Veritas。

  • - Analyst

    - Analyst

  • Hi, Mike. Thanks a lot for taking my call.

    嗨,Mike。非常感謝接聽我的電話。

  • So I have two questions. One relates to the $58 million restatement. I was wondering if you can elaborate whether that restatement primarily related to Q4, and if you could break out the deals by products, what products is related. Now if you can potentially quantify that.

    我有兩個問題。一個與 5,800 萬美元的重述有關。我想請你進一步說明,該重述是否主要與第四季相關;另外如果可以按產品拆分交易,涉及哪些產品?如果可能的話,請量化一下。

  • And the other question has to do with the change in tax presentation. So, can you please clarify on Slide 6, when you talk about Q4 2015 on order of results there. Is this the old presentation, or is that the new presentation? I'm talking about the middle section of the slide.

    另一個問題與稅務呈現方式的變更有關。所以,請你釐清一下在第 6 張投影片,當你談到 2015 年第四季的訂單結果時。那是舊的呈現方式,還是新的呈現方式?我指的是投影片中間那一段。

  • And if you can also elaborate what you mean by tax provision there. Is that tax provision that includes both deferred, as well as current income taxes? Or is it something else? And the same thing obviously applies to FX or non-GAAP adjustments; is it related to deferred or current taxes? Thank you very much.

    另外也請你說明你在那裡所說的稅費提列(tax provision)是什麼意思。那個稅費提列是否同時包含遞延所得稅與當期所得稅?還是指其他項目?同樣地,這也顯然適用於外匯或非 GAAP 調整;它是與遞延稅或當期稅相關嗎?非常感謝。

  • - CEO

    - CEO

  • So in terms of the ad hoc committee, I think, put out a press release that talked about the timing in 2014 of what was $68 million -- $58 million, in terms of Q4 2014 versus Q1 2015. So that is what happened.

    就臨時委員會而言,我想他們發布了一份新聞稿,談到 2014 年的時間點問題,金額是 6,800 萬美元——5,800 萬美元,涉及 2014 年第四季與 2015 年第一季之間。所以事情就是那樣。

  • - Analyst

    - Analyst

  • So it's all Q4, really.

    所以其實全都在第四季。

  • - CEO

    - CEO

  • The second half. But is primarily Q4. In terms of the mix of products, we took a look at that. It's a normal mix. It would -- you may referring -- there was some -- I had heard some speculation that it was all Solodyn or something like that, which is not true. It was a normal mix across our dermatology, primarily our dermatology product portfolio. Rob, tax?

    在下半年。但主要是在第四季。至於產品組合,我們也檢視過。那是正常的組合。你可能指的是——之前我聽到一些猜測說全部都是 Solodyn 或類似產品,但那不是真的。那是我們皮膚科產品組合中的正常組合,主要來自我們的皮膚科產品組合。Rob,稅務?

  • - CFO

    - CFO

  • Two things. The middle part of the chart is the way we are presenting the press tables that were released this morning. Where we're breaking out for the first time, the tax provision plus the FX, the non-GAAP adjustments, which are there both current and deferred on an ongoing basis.

    兩點。圖表中間那一部分,是我們在今天早上發布的新聞表格中所採用的呈現方式。我們首次把稅費提列加上外匯、非 GAAP 調整分開列示;這些在持續性基礎上同時包含當期與遞延。

  • From the other going forward, what we will report is just that first term. So if you look at Tables 2a and 2b, it's the first term that we will report and we will apply that to calculate our adjusted EPS. And so therefore, our reported tax rate, again on a comparable basis, and this will change if we delever and reduce our NOLs, would move from approximately 5% to approximately 10% to 15%.

    往後我們將報告的只有第一個項目。所以如果你看表 2a 和 2b,我們將報告的是第一個項目,並用它來計算調整後 EPS。因此,我們的申報稅率(在可比基礎上),而且如果我們去槓桿並降低 NOL(淨營運虧損結轉),這個數字會改變,將會從約 5% 上升到約 10% 到 15%。

  • - CEO

    - CEO

  • My understanding, that's the last question. So we appreciate everyone's patience. We look forward to our next call. Thank you.

    我的理解是,那是最後一個問題。所以我們感謝大家的耐心。期待下一次電話會議。謝謝。

  • Operator

    Operator

  • This concludes today's conference call. You may now disconnect.

    今天的電話會議到此結束。您現在可以掛線。